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ABSTRACT 
 
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects up to 1% of 
the population. The importance of tumour necrosis factor (TNF) in RA has been 
established and anti-TNF biologics have proved to be highly effective in reducing 
inflammation. However, a proportion of RA patients fail to adequately respond to 
anti-TNF and even those who do respond have residual pain. This has prompted the 
investigation into other cytokines, such as interleukin-17 (IL-17), as potential new 
targets.  
This study sought to investigate the contribution of IL-17 to acute or chronic 
hyperalgesia. C57BL/6 mice were injected with recombinant IL-17. This induced a 
transient hyperalgesia, which was found to be dependent both on neutrophil 
migration and signalling through TNFR1. Using the air pouch model of cell 
migration, it was confirmed that the cell infiltration was associated with increased 
expression of the chemokine keratinocyte attractant (KC). These results suggest that 
IL-17 induces acute hyperalgesia by inducing TNF from resident cells.  
 To investigate IL-17 and chronic hyperalgesia, the collagen induced arthritis 
mouse model (CIA) was used. IL-17RA was found to be up regulated in both the 
paw and in the dorsal root ganglia in arthritis, suggesting a role for IL-17 in chronic 
hyperalgesia. IL-17 blockade proved to be anti-arthritic and analgesic during CIA 
and potently reduced expression of pro-inflammatory cytokines.  
This study confirms that IL-17 contributes to acute and chronic hyperalgesia but 
acts in part via the induction of TNF.  
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1.1 Rheumatoid Arthritis 
 
1.1.1 Disease classification and description 
 
Rheumatoid arthritis (RA) is a debilitating and progressive autoimmune condition 
affecting around 1% of the population. Although the cause of RA is unknown, 
genetic and environmental factors contribute to disease susceptibility. Symptoms of 
RA include inflammation of the joints causing difficulty with mobility and chronic 
pain. This can then develop into severe disability with irreversible cartilage 
destruction, bone erosion, joint deformity and reduced quality of life (Feldmann and 
Maini 2001). The diagnosis of RA is based on a number of criteria as described by 
the American College of Rheumatology as shown in Table 1.1 (Aletaha, Neogi et al. 
2010). 
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(Aletaha, Neogi et al. 2010) 
 
 
 
The most frequent age of onset of RA is 40-60, but it can develop at any time and 
affects three times as many women as men (Lee and Weinblatt 2001). Drugs 
targeting the inflammatory response have been successful, but for many the pain 
relief is unfulfilled (Breivik, Collett et al. 2006). Through a greater understanding of 
the inflammatory and pain processes involved in RA, more effective drugs to 
combat this disease and its associated pain can be developed. 
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1.1.2 Aetiopathogenesis of Rheumatoid Arthritis 
 
RA is characterised by proliferation of the synovial lining layer and infiltration of 
the joints by a variety of leukocytes including T and B lymphocytes, macrophages 
and neutrophils (Figure 1.2). The presence of leukocytes leads to release of many 
factors, including proinflammatory cytokines, prostaglandins and matrix 
mellatoproteinases (MMPs). The leukocytes together with synoviocytes form 
pannus, a tissue that grows over the articular cartilage. The articular cartilage is 
progressively destroyed and the underlying bone eroded (Firestein 2003; Smolen 
and Steiner 2003).  
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A combination of genetic, infectious, and environmental factors are thought to 
initiate RA and contribute to its severity. The major histocompatibility complex 
(MHC) is a gene family separated into 3 classes. Class II molecules are located on 
antigen presenting cells (APCs) where they express antigens to CD4+ T cells and 
are thought to be important in the initiation and/or progression of RA. Genetic 
susceptibility to RA is associated with specific alleles within MHC class II 
(Newton, Harney et al. 2004). Certain HLA DRB1 alleles are found in increased 
frequency in patients with RA compared to healthy controls (McInnes and Schett 
2007). These alleles share a common sequence, which is termed the shared epitope 
(SE). Around 90% of RA patients are positive for this SE (Gregersen, Silver et al. 
1987), however whether being positive for this shared epitope confers susceptibility 
or signals a more progressive disease is a matter of some debate (Fugger and 
Svejgaard 2000; Taneja, Behrens et al. 2008; Taneja and David 2010).  
 
RA diagnosis is also associated with the production of autoantibodies (Table 1.1). 
The presence of rheumatoid factor (RF) has long been a diagnostic tool for RA 
(Arnett, Edworthy et al. 1988). RF is detected in 70-90% of RA patients, but is also 
present in healthy individuals, and patients with other autoimmune diseases 
(Dorner, Egerer et al. 2004; Dorner and Hansen 2004). Although widely used, RF is 
not as specific or as sensitive as anti-cyclic citrullinated peptide (anti-CCP) Ab 
(Klareskog, Ronnelid et al. 2008; Snir, Widhe et al. 2010). Anti-CCP Ab is 
recognised as having an equal sensitivity but higher specificity (97%) for RA than 
RF and is now considered a more useful marker (Silveira, Burlingame et al. 2007). 
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1.1.3 Treatment of RA 
 
RA therapy has traditionally been dominated by use of non-steroidal anti-
inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs 
(DMARDs). NSAIDs target prostaglandin synthesis by inhibiting cyclooxygenase 
(COX) I and/or II (Vane 1976). Blockade of COX-II is beneficial in treating RA 
pain and inflammation (Samad, Moore et al. 2001; O'Dell 2004), but does not slow 
disease progression (Smolen and Steiner 2003). Many NSAIDs also suppress COX-
1 which leads to peptic ulceration and gastric haemorrhage (Crofford 1997; Singh 
1998; O'Dell 2004). The toxicity of NSAIDs discouraged their long-term use in RA. 
NSAIDs may be taken in combination with synthetic DMARDs (e.g. methotrexate). 
Synthetic DMARDs impede RA progression but are slow acting and have a limited 
efficacy (Smolen and Steiner 2003). To develop a more effective therapy, the 
pathogenesis of RA was further investigated. The pivotal involvement of 
proinflammatory cytokines including TNF in RA was then established.  
 
The realisation that TNF was critical in RA followed a series of key studies. Firstly, 
TNF blockade was found to down regulate production of IL-1 from RA 
synoviocytes and indicted that TNF was the main inducer of IL-1 (Brennan, 
Chantry et al. 1989). Granulocyte macrophage colony stimulating factor (GM-CSF), 
also implicated in RA progression, was also found to be dependent on TNF 
(Haworth, Brennan et al. 1991). Secondly, TNF was present in rheumatoid synovial 
tissues but not in normal synovial membrane (Chu, Field et al. 1991). It was then 
shown that by neutralising TNF in a mouse model of arthritis, inflammation was 
ameliorated and the joint destruction impeded (Williams, Feldmann et al. 1992). 
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Blockade of TNF also protected hTNF transgenic mice from cachexia (wasting 
syndrome) and TNF-induced mortality (Siegel, Shealy et al. 1995). The efficacy of 
anti-TNF in animal models prompted the successful use of the drug in clinical trials 
(Elliott, Maini et al. 1994; Elliott, Maini et al. 1994; Elliott, Feldmann et al. 1995). 
However, as the drug (infliximab) was a chimeric (human/mouse) mAb it was 
feared that it would lose efficacy over a prolonged period of time because of anti-
globulin responses (Feldmann and Maini 2003). This was overcome by combining 
infliximab with methotrexate, and 60-70% patients responded with a 20% 
improvement in symptoms, while around 40% patients achieved a 50% 
improvement (Maini, Breedveld et al. 1998). Similar success was then achieved 
with new anti-TNF biologics etanercept (Moreland, Schiff et al. 1999; Weinblatt, 
Kremer et al. 1999) and fully human adalimumab (Weinblatt, Keystone et al. 2003). 
However, as anti-TNF is not effective  in all patients, other proinflammatory 
cytokines such as IL-17 are being investigated as potential additional targets. 
 
Inadequate pain relief is a common problem in RA patients. For example, it was 
reported that around 60% of patients with chronic pain visit their doctor about their 
symptoms an average of 2-9 times in 6 months, (Breivik, Collett et al. 2006). 
Therefore a decrease in pain score as measured by the American College of 
Rheumatology (ACR) is a desirable goal in clinical trials. Traditionally, 
rheumatologists have approached pain relief by targeting local inflammation 
(Borenstein 2010). However, chronic pain is typified by changes in central 
sensitisation. This means that chronic pain can persist long after the peripheral 
damage has healed and can develop in normal tissues away from the original site of 
inflammation (Woolf 2004; Kidd, Langford et al. 2007). Chronic pain is not just 
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governed by tissue damage but by gender, environmental, and psychological factors 
(Kidd, Langford et al. 2007; Keefe and Somers 2010). Pain perception is therefore 
individual and subjective, and pain relief needs should be addressed on a patient by 
patient basis.  
 
Current analgesics used in RA pain management are NSAIDs (Kean and Buchanan 
2005), often in combination with other analgesic agents such as paracetamol 
(Graham, Day et al. 1999). RA patients treated with anti-TNF biologics have 
reported rapid analgesia (Kidd, Langford et al. 2007) . However many remain on 
additional pain medication, suggesting that any analgesia from anti-TNF is 
potentially indirect. Further study is needed to understand the relationship between 
TNF and pain pathways. 
 
Pain management in RA is now also being tackled using pain coping skills training 
(PCST). PCST provides training in coping strategies in challenging pain situations 
and RA patients receiving this therapy demonstrate enhanced pain control (Keefe 
and Somers 2010).  
 
Pain in RA is governed by multiple events, including peripheral inflammation and 
plasticity of the peripheral and central nervous system. By understanding the 
mechanisms driving this process and the method of action of analgesics, a more 
refined, effective pain therapy can be designed. 
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1.2 Animal models of arthritis  
 
Animal models are used to investigate aspects of RA by identifying potential 
mediators of the disease and test efficacy of novel therapeutics in vivo (Asquith, 
Miller et al. 2009). TNF was identified as a key target in RA, with the transfer of the 
drug to the clinic facilitated by the successful treatment of animal models of 
arthritis. More recently, these models are being used to assess acute and chronic 
pain, and to test drugs as analgesics (Inglis, Notley et al. 2007; Boettger, Hensellek 
et al. 2008). Animal models of arthritis are described in brief in Table 1.2 adapted 
from (Inglis 2010).  
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1.2.1 Adjuvant Induced Arthritis 
 
Adjuvant arthritis (also known as CFA induced arthritis) is induced via a single 
injection of Complete Freund’s adjuvant (Incomplete Freund’s adjuvant plus 
Mycobacterium tuberculosis) (Pearson 1956). Injected at the base of the tail in 
susceptible strains it induces poly arthritis within 10-45 days post-injection. 
Features of this model include oedema, leukocyte infiltration into the joint, pannus 
formation, and cartilage and bone erosion. The disease in general subsides after one 
month, unlike RA (Williams 1998). Although the mechanism of CFA arthritis 
remains unclear, there is an elevation in the activity of antigen-presenting cells 
(APCs) following immunisation. This would lead to presentation of the 
unrecognised endogenous antigen to auto-reactive T cells. Alternatively, CFA is 
injected into the hind paw where a mono arthritis is rapidly achieved by infiltration 
of inflammatory cells, pannus formation and cartilage loss. Proinflammatory 
cytokines such as TNF and IL-6 are increased in the affected paw within 3h post 
injection. CFA paw injection has been extensively studied in inflammatory pain 
research (Larson, Brown et al. 1986; Walker, Fox et al. 1999).  
 
1.2.2 Zymosan-induced arthritis 
 
Zymosan is a polysaccharide derived from the cell wall of Saccharomyces 
cerevisiae. When injected into the murine joint, an acute inflammatory arthritis 
develops within three days, subsides by day 7 and re-activates by day 25 (Keystone, 
Schorlemmer et al. 1977). Like CFA injection into the paw, it is a mono arthritis. 
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Zymosan induced arthritis (ZIA) is characterised by synovitis, pannus formation 
and cellular infiltration. Zymosan is a ligand for toll-like receptor (TLR) 2, which 
induces proinflammatory cytokines from macrophages, thereby initiating disease 
(Frasnelli, Tarussio et al. 2005). 
  
1.2.3 Antigen-Induced Arthritis 
 
Antigen-induced arthritis (AIA) develops following intra-peritoneal injection of 
methylated bovine serum albumin (mBSA) into animals that have previously been 
immunised with the same antigen (Brackertz, Mitchell et al. 1977). A mono arthritis 
then develops with leukocyte infiltration into the knee joint, proliferation of the 
synovial lining layer, pannus formation and cartilage and bone erosion. The disease 
however, does not spread beyond the injected joint (Williams 1998).  
 
 
1.2.4 Streptococcal Cell Wall-Induced Arthritis 
 
Sonicated streptococcal cell walls (SCW) are injected intra-articular into the animal 
knee joint. This is followed by a second dose into the tail vein into susceptible rats 
or mice resulting in a phasic disease of acute inflammation, remission, and then 
chronic monoarthritis (Esser, Stimpson et al. 1985; Wilder 1988). The SCW joint 
bears similarities to RA including infiltration of macrophages, CD4+ T cells and 
neutrophils, plus pannus, cartilage destruction and bone erosion. Like other forms of 
monoarthritis, it is limited by a lack of systemic effects. 
 
                                                                                                                    Chapter 1: Introduction 
 
12 
 
 
 
1.2.5 Spontaneous Arthritis in Transgenic Strains of Mice 
 
1.2.5.1 hTNF and hIL-1α transgenic mice 
 
Mice overexpressing a human TNF transgene develop spontaneous arthritis by 4 
weeks of age, which is prevented by continuous treatment with anti-human TNF 
monoclonal antibody. Although TNF is over expressed systemically, it is the joints 
that are largely affected, supporting the finding that TNF is a key mediator of RA 
(Kollias, Douni et al. 1999). In addition, another TNF overexpressing transgenic 
mouse has been created known as TNF
ΔARE
. TNF
ΔARE
 mice prevent TNF mRNA 
destabilisation, effectively removing the brake on TNF production, resulting in TNF 
overexpression. As well as spontaneous arthritis, these mice also present with 
inflammatory bowel disease, highlighting the fact that TNF is important in other 
forms of autoimmunity (Kontoyiannis, Pasparakis et al. 1999).  
 
IL-1 has been shown to be a major mediator of arthritis, and human IL-1 
transgenics, like hTNF mice have a severe polyarthritis by 4 weeks of age (Niki, 
Yamada et al. 2001). In all these models there is synovial lining layer hyperplasia, 
pannus, degradation of cartilage and loss of function. 
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1.2.5.2 The K/BxN model 
 
The K/BxN model of arthritis arose from transgenic mice that express a T-cell 
receptor (TCR) specific for a peptide from bovine pancreatic ribonuclease in the 
context of I-A
k
 (Peccoud, Dellabona et al. 1990). These transgenic mice 
spontaneously exhibit a form of chronic progressive arthritis with many similarities 
to RA when bred on to the non-obese diabetic (NOD) background (Kouskoff, 
Korganow et al. 1996). The unusual MHC class II allele derived from the NOD 
mouse (H-2
g7
) was found to be sufficient to confer susceptibility to spontaneous 
disease. Further studies revealed that arthritis could be transferred by injecting naive 
mice with serum IgG from arthritic mice in a complement- and FcR-dependent 
manner, indicating the pathological role played by autoantibodies in this model 
(Korganow, Ji et al. 1999). The molecular target of the autoantibodies was then 
identified as glucose-6-phosphate isomerase (GPI), a ubiquitous cytoplasmic 
enzyme found to accumulate on the lining of the articular cavity, particularly on the 
cartilage surface (Matsumoto, et al 2002). The particular relevance for human RA is 
that arthritis may arise as a result of an immune response to an antigen that is not 
confined to the joint. Therefore, the assumption that RA results from an aberrant 
autoimmune response to an antigen in the joint may not be valid. 
 
1.2.5.3 SKG mice 
 
SKG mice develop a spontaneous inflammatory arthritis at around 8 weeks of age 
due to a point mutation in ZAP-70. ZAP-70 is a T cell signal transduction molecule 
and its mutation altered T-cell receptor signalling, leading to selection of 
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autoimmune T cells due to a failure in thymic deletion. This arthritis is dependent 
on the murine local environment, as disease does not occur in germ-free conditions. 
Features of this disease are also similar to aspects of RA pathology, including 
involvement of many joints, synovitis, pannus formation and loss of function 
(Sakaguchi, Takahashi et al. 2003). 
 
1.2.6 Collagen-Induced Arthritis 
 
Collagen induced arthritis (CIA) is the most widely-used model for translational RA 
research due to its pathological similarity to RA (Holmdahl, Andersson et al. 1989). 
Immunization of primates, rats or mice with foreign type II collagen in adjuvant 
induces polyarthritis. In mice, an intra dermal injection of bovine or chicken type II 
collagen in CFA induces onset of arthritis around 14-28 days post immunisation. 
Like RA there is synovitis, immune cell infiltration, pannus formation, bone 
erosion, loss of function (Trentham 1982) and chronic pain (Inglis, Notley et al. 
2007). Susceptibility to CIA is linked with MHC class II genes and DBA/1 mice 
classically used bear one of these MHC susceptible haplotypes (I-Aq) making it an 
ideal strain for this disease (Holmdahl, Karlsson et al. 1989; Holmdahl 2003). 
Unlike human RA, CIA in DBA/1 mice is relatively acute but like RA features 
elevated proinflammatory cytokines, including TNF, IL-1, IL-17 and IL-6, in the 
arthritic joint (Marinova-Mutafchieva, Williams et al. 1997; Lubberts, Joosten et al. 
2001; Murphy, Langrish et al. 2003). Blockade of these cytokines reduces clinical 
score, paw swelling, histological changes and pain (Williams, Feldmann et al. 1992; 
Alonzi, Fattori et al. 1998; Lubberts, Koenders et al. 2004; Inglis, Notley et al. 
2007). 
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However, investigating the role of poorly characterised mediators is facilitated by 
the use of transgenic and knockout mice. In general, these animals are bred on a 
C57BL/6 background. This represents a problem as the C57BL/6 strain is resistant 
to bovine type II collagen induced arthritis. However, my colleagues and I have 
now established that C57BL/6 mice are susceptible to CIA when chicken type II 
collagen is used for immunisation. CIA in C57BL/6 mice is a milder, more chronic 
disease, but still marked by synovitis, immune cell infiltration, pannus formation, 
bone erosion and loss of function (Inglis, Criado et al. 2007; Inglis, Simelyte et al. 
2008). Anti-TNF biologics are also highly effective in treating C57BL/6 CIA, 
making this strain a valuable alternative to DBA/1 strain (Inglis, Criado et al. 2007).  
 
1.3 Chronic pain 
 
1.3.1 Pain definitions 
  
The sensation of pain is an unpleasant event associated with actual or ensuing tissue 
damage (For further classification see Table 1.3). Pain (known as nociception) is 
normally in response to noxious stimuli, usually localised to the site of injury and 
diminishes when the stimulus is removed. This pain is managed by high threshold 
neurons in the peripheral and central nervous system. However, tissue damage can 
lead to an enhanced pain state due to a lower activation threshold of sensitised nerve 
fibres (Woolf and Ma 2007). This chronic pain is not useful for tissue protection 
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and is disabling. Pain (dolor) is one of the hallmarks of inflammation  along with 
heat (calor), redness (rubor) and swelling (tumor). 
 Rheumatoid arthritis patients present with hyperalgesia (increased pain upon 
noxious stimuli) and allodynia (an exaggerated pain response caused by a non-
painful stimulus) as well spontaneous pain (Schaible, Ebersberger et al. 2002).  
 
 
1.3.2 Mechanisms of peripheral and central sensitisation 
 
Peripheral sensitisation occurs due to a reduction in the threshold of nociceptors. 
After tissue damage, chemical mediators are released at the site by resident cells or 
by infiltrating immune cells. Some like ATP, protons, or 5-hydroxytryptamine can 
directly activate the nociceptors, eliciting a pain response. Other mediators released 
by immune cell such as prostaglandin (PGE2), or bradykinin increase the 
responsiveness of the nociceptor, thereby reducing the threshold for activity.  
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 The mechanisms responsible for peripheral sensitisation are governed by post-
translational processing (phosphorylation) and changes in gene expression 
(alterations to the protein made by the nociceptor) of proteins and ion channels that 
determine the excitability of the nociceptor. These proteins and ion channels are 
imperative for converting a stimulus into electrical activity, resulting in an action 
potential (Woolf and Salter 2000). Phosphorylation is the addition of phosphate 
groups to a protein’s amino acids via kinase enzymes and can alter the function of 
the protein. This alteration can manifest in increasing the excitability or reducing 
the temperature needed to open an ion channel (e.g. Nav1.8 and TRPV1 
respectively) (Gold, Levine et al. 1998; Premkumar and Ahern 2000; Bhave and 
Gereau 2004). Phosphorylation can also affect how long the ion channel is open for, 
increasing the effect of the stimulus on the nociceptor. Inflammatory mediators like 
PGE2 act locally to provoke a rise in cAMP, which activates protein kinase A 
(PKA), a kinase important in phosphorylation (Taiwo and Levine 1991; Kress, Rodl 
et al. 1996; Bhave and Gereau 2004). In addition, some proteins are transported 
along the axon of the nerve fibre to the cell body of the nerve in the dorsal root 
ganglia (DRG). Once in the cell body, the protein can alter transcription to increase 
expression of certain genes and affect translation to enhance production of 
particular proteins. These proteins are shuttled back to the terminal of the nociceptor 
to assist in enhancing the nociceptor activity (Dubner and Ruda 1992; Woolf and 
Costigan 1999; Ji and Woolf 2001). 
 
 Central sensitization occurs when neurons in the central nervous system have 
enhanced excitability. This results in an abnormal response from an innocuous 
input.  Increased activity of peripheral nociceptors (in response to tissue injury) 
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leads to a change in the synaptic connection between the nociceptor and the central 
neurons of the spinal cord. This is also known as synaptic plasticity. Like peripheral 
sensitisation, the process is moderated by phosphorylation and changes in gene 
expression. After a signal has been received from the periphery, the central terminal 
of the nociceptor releases neurotransmitter (glutamate), neuropeptides (substance P) 
and synaptic modulator proteins (BDNF). Production of these mediators results in 
phosphorylation of membrane receptors and channels via kinases, leading to 
increased excitability of the neurons (Woolf and Thompson 1991; Yashpal and 
Henry 1993; Woolf and Salter 2000; Kuner 2010). A later phase of central 
sensitisation is due to increased protein production of inflammatory mediators, 
which through promoting kinases and therefore phosphorylation targets, maintain 
excitability, resulting in persistent, chronic pain (Dubner and Ruda 1992; McCarson 
and Krause 1994; Michael, Averill et al. 1997; Mannion, Costigan et al. 1999; 
Latremoliere and Woolf 2009).   
 
 
1.3.3 Methods of pain detection in rodents 
 
Pain detection in humans largely relies on communication. Understanding the 
location, nature and intensity of the pain and how it affects the patient’s activity is 
important in assessing how effective analgesics are.  Rodents cannot communicate 
information regarding their pain in the same way, but their activity is similarly 
affected. In humans, facial expressions can also denote pain, and recently the mouse 
grimace scale (MGS) was developed to measure spontaneous pain using mouse 
facial changes during pain (Langford, Bailey et al. 2010). Traditionally, pain in 
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rodents can be quantified by response to a stimulus or by measuring spontaneous 
activity (Inglis 2010).  
  Evoked pain response is a simple and rapid way of detecting 
hyperalgesia. The most common methods involve applying a stimulus to the paw 
and measuring the time for the rodent to remove the paw from the stimulus. 
Withdrawal is often accompanied by licking the paw. The Hargreaves test applies 
an increasing thermal stimulus to the hind paw (Inglis, Notley et al. 2007), and the 
Von Frey hairs are administered to the paw in increasing thickness, delivering a 
force stimulus (Inglis, Nissim et al. 2005). When a rodent has hyperalgesia or 
allodynia, the time taken to elicit a painful response is reduced. In healthy mice for 
example, the thermal pain response is typically between 8-12 seconds, but in mice 
with hyperalgesia this is decreased to 1-4 seconds. These tests have the advantage of 
being applicable to poly arthritis models as well as mono-arthritis and acute 
hyperalgesia models. If only 1 hind paw is involved, then an additional non-evoked 
test (Linton incapacitance tester) can be used.  
 
The Linton incapacitance tester is divided into two weighing scales. The animal is 
placed inside the chamber with one paw on each weighing platform. The weight on 
each platform is measured and animals with enhanced pain will lean to their 
unaffected side (Inglis, McNamee et al. 2008; McNamee, Burleigh et al. 2010).  
General day-to-day activity is often affected in patients with chronic pain; therefore 
it is important to investigate general behaviour and activity in rodents. Mice with 
CIA have reduced climbing, grooming and locomotion, and increased immobility 
(Inglis, Notley et al. 2007). LABORAS (Laboratory Animal Behaviour Observation 
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Registration and Analysis System) converts the vibrations created by the mice into 
activity. With all tests mentioned here, effective analgesics will restore a normal 
pain response in rodents (Inglis, Notley et al. 2007; McNamee, Burleigh et al. 
2010). 
 
 
1.4 Cells of the Peripheral and Central Nervous System 
 
1.4.1 Cells of the Peripheral Nervous System 
 
The peripheral nervous system (PNS) consists of all nerves and nerve-related cells 
outside of the central nervous system (CNS) whose function is to provide a link 
between the CNS and the periphery (Olsson 1990).  
 
Accompanying the peripheral neurons are Schwann cells which wrap around the 
axon of the neuron.  Schwann cells are support cells that provide insulation by 
producing myelin for myelinated nerves, but are now thought to have additional 
immune functions. Indeed, Schwann cells are also present in unmyelinated nerves, 
where they are considered to be vital for the maintenance of these axons and pain 
sensation (Griffin and Thompson 2008). In mice, when communication between the 
unmyelinated axons and non-myelinating cells is impaired (via disruption of 
Neuregulin 1 signalling), they become progressively insensitive to heat and cold 
stimuli (Chen, Rio et al. 2003). Schwann cells express proinflammatory cytokines 
and MHC II after injury, with TNF thought to be important for their activation. 
Although little is understood about the function of Schwann cells besides the 
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production of myelin, it is suggested that they provide an early defence for the PNS 
neurons during immune cell infiltration after nerve injury (Armati 2007; Griffin and 
Thompson 2008). 
 
Satellite cells are glial cells that cover the outside of the neuron cell body and 
studies regarding their role are limited. Their main function appears to be regulation 
of the nerve environment, but like Schwann cells, they can express TNF and other 
pro-inflammatory cytokines when activated (Armati 2007; Takeda, Takahashi et al. 
2009). In addition to the nerve-related cells there are reported to be resident 
macrophages (around 9%) and T cells, which can produce cytokines and 
chemokines to facilitate immune cell infiltration (Scholz and Woolf 2007).  
 
1.4.2 Cells of the Central Nervous System 
 
The CNS is composed of the brain and the spinal cord and contains two major cell 
types; the neurons and the glia. Although CNS neurons are the functional cells 
needed for pain transmission, they are not the dominant cell type in the CNS, 
accounting for only about 10% of the cell population.  
 
Spinal neurons are separated into three main classes. Sensory neurons take 
information (such as pain transmission) away from the periphery via the dorsal horn 
into the CNS but also project to interneurons in the cord where there activity is 
modified prior to signal relay. Motor neurons follow sensory input and transmit 
signals back from the CNS via the ventral horn and synapse in the periphery, 
controlling motor function (including movement away from a pain source). 
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Interneurons have axons retained entirely in the CNS and are largely inhibitory. 
Interneurons act as a connector between sensory and motor nerves, relaying 
information from the sensory nerve to the motor nerve. The white matter contains 
the axons of the nerves, while the cell body and dendrites are retained in the grey 
matter (Burke 1977; Brown 1981).  
 
Glia cells in the CNS are made up of astrocytes and microglia. Astrocytes 
outnumber neurons 5-10 fold, and in common with neurons, originate from the 
neural crest. Traditionally, these cells were thought of as having a passive function, 
acting as structural support for the neurons, and maintaining homeostasis. However, 
it is now known that as well as regulating the neural microenvironment, astrocytes 
have an active and vital role in healthy and diseased CNS tissue (Sofroniew and 
Vinters 2010). Astrocytes are star shaped cells with processes radially extending 
from the cell. The extended branches of the astrocytes are vital for maintaining 
contact with blood vessels and monitoring CNS blood flow. In addition, it has been 
suggested that astrocytes are important in blood-brain barrier (BBB) development 
and integrity (Bush, Puvanachandra et al. 1999; Sofroniew and Vinters 2010). Glial 
fibrillary acid protein (GFAP) is a classic marker for identification of these cells by 
immunohistochemistry and is present in the processes. Upon astrocyte activation 
(astrogliosis), GFAP expression increases as the cell processes extend (Hald 2009). 
Astrogliosis occurs during CNS trauma or disease, and chronic pain states (Inglis, 
Notley et al. 2007; Hald 2009). A link between astrocytes and chronic pain was first 
addressed by demonstrating that increased GFAP correlated with hyperalgesia in a 
chronic constriction nerve injury (CCI) model (Zhang and De Koninck 2006; Hald, 
Nedergaard et al. 2009). Since then, astrogliosis has been reported in a variety of 
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neuropathic and inflammatory pain models, including CIA (Inglis, Notley et al. 
2007).      
 
Although there is evidence for astrocytic involvement during chronic pain, there is 
less to suggest the same for the microglia. Microglia are CNS immune cells with a 
haematopoietic origin (Perry and Gordon 1988; Flaris, Densmore et al. 1993; 
Scholz and Woolf 2007). In healthy CNS tissue they maintain a quiescent 
phenotype, but are not silent. Resting microglia maintain the local environment, 
including synapses, and survey CNS tissue for pathogens (Kreutzberg 1996). After 
stimulus from injury or infection, they become active and then phagocytic, and are 
necessary for CNS protection. However, activated microglia are also cytotoxic, 
which can result in neuronal cell death (Graeber and Streit 2010). Microglia are 
implicated in degenerative disorders such as Parkinson’s, Alzheimer’s and multiple 
sclerosis (MS) (Graeber and Streit 2010), but there is limited evidence to suggest 
they are important in arthritis. Microglial activation has been reported in CFA 
induced arthritis and AIA (Wu, Zhang et al. 2005) (Bao, Zhu et al. 2001), but is not 
detected in CIA (Inglis, Notley et al. 2007). 
 
1.5 Pain Pathways  
 
1.5.1 Peripheral afferent fibres  
 
Nociceptive information is transmitted from the periphery to the spinal cord (and 
then onto the brain) by peripheral sensory neurons also known as peripheral afferent 
fibres, or PAFs (LaMotte and Campbell 1978; Treede 1995; Hunt and Mantyh 
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2001). PAFs can be broadly divided into three subsets, Aß, Aδ and C fibres 
depending on their diameter and conduction velocity (Table 1.4). The PAFs cell 
body is located in the dorsal root ganglia (DRG) but the axons project as far as the 
dorsal horn of the spinal cord when they synapse to relay the information into the 
CNS. The dorsal horn is organised into sections called laminae. The lamina that the 
PAF terminates in differs for each subset (Averill, Davis et al. 2002). Aß PAFs are 
large in diameter (<10m), myelinated axons with a low threshold for activation 
and rapid conduction velocity of 30-100ms
-1. In the healthy individual, Aβ-fibres 
transmit proprioceptive information, such as joint movement, or pressure. Aβ fibres 
have two projections, one terminating in the inner laminae III/IV and one in lamina 
V.  
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A-fibres have a medium axonal diameter of 2-6m, and are thinly myelinated, 
with a conduction velocity of 12-30ms
-1
 and a medium threshold for activation. The 
majority of Aδ fibres transmit nociceptive information, specifically inducing a rapid 
acute pain sensation after a noxious stimulus. Aδ fibres project to lamina I and V. 
Finally, C-fibres are high threshold unmyelinated neurones with a small diameter of 
0.4-1.2μm and a conduction velocity of 0.2-2ms-1. Almost all C fibres are 
responsible for nociceptive transmissions, but being unmyelinated are slower, 
eliciting a dull secondary pain. C fibres are further divided into peptidergic or non 
peptidergic depending on the neurochemical expressed. (Millan 1999; Melzack 
2006; Inglis 2010)
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Peptidergic fibres express calcitonin gene related peptide (CGRP), and make up 
around 40% of the rat L4 and L5 DRG (Millan 1999). Around 92% of these fibres 
express the NGF receptor TrkA and are NGF-dependent for development and 
survival (Henderson 1996) (Averill, McMahon et al. 1995). Non-peptidergic fibres 
bind Griffonia simplicifola isolectin B4 (IB4), and also express the ATP receptor, 
P2X3. These account for approximately 30% of DRG cells in rodents (Averill, 
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Davis et al. 2002). There is overlap between these two populations of neurones, 
with around 10-15% C-fibres expressing both P2X3 and CGRP (Millan 1999) 
(Figure 1.2). Many sub-populations of nociceptive neurones are contained within 
peptidergic and non-peptidergic fibres. Furthermore, it is important to note that 
there are reported differences in C fibres between rats and mice. Over 50% of non-
peptidergic neurons in rats also express TRPV1. However, in mice only 6% of non-
peptidergic C fibres expressed both IB4 and TRPV1 suggesting that certain pain 
pathways may be regulated differently depending on the species (Zwick, Davis et al. 
2002). Peptidergic C fibres synapse in lamina I and the outer side of lamina II, 
where as non-peptidergic project further into the inner lamina II (Scholz and Woolf 
2007).  
 
1.5.2 Lamina projections 
 
Deep laminae (III-V) (Aß and Aδ fibres) project to lateral reticular nucleus (LRN), 
subnucleus reticcularis dorsalis (SRD) and the giantocellular/lateral 
paragigantocellular reticular nuclei (NGc) (all located in the medulla and project to 
the cerebellum). The cerebellum is ‘motor function’ area of the brain and this 
system could be responsible for the physical reaction upon receiving a painful 
stimulus.  
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Superficial laminae (I-II) are where Aδ and C fibres terminate (Figure 1.7). Lamina 
I project to lateral parabrachial area and the caudal area of the lateral thalamus, 
namely the ventral posterolateral nucleus (VPL), the ventral posteromedial nucleus 
(VPM) and the central nucleus for the amygdala (CeL). As the superficial laminae 
are the prime targets for the Aδ and C PAFs, and the amygdala is the centre for 
emotional reaction, it would follow that these laminae are involved in pain sensation 
and emotional response. However, C fibres project to different lamina depending on 
whether they are peptidergic or non peptidergic, suggesting further alternate 
pathways. Peptidergic fibres project to lamina I suggesting that they are the major 
fibres for pain sensation and emotional response. Non-peptidergic fibres largely 
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project to the inner laminae and therefore are likely to regulate motor response after 
pain sensation (Inglis 2010). 
 
1.6 Inflammatory mediators of nerve sensitisation 
 
Tissue damage results in release of inflammatory mediators from the injured 
resident cells. Some of these mediators directly sensitise the peripheral nociceptors 
by lowering their activation threshold. However, other mediators act indirectly 
through the recruitment of immune cells that release further inflammatory proteins 
that induce additional directly sensitising agents.  
 
1.6.1 Nerve growth factor and prostaglandins 
 
Nerve growth factor (NGF) is required to promote survival of sensory neurones 
before birth and growth and neurotransmission after birth. NGF administration 
induces hyperalgesia in humans (Kidd and Urban 2001) and rodents. It is thought 
that NGF mainly directly on sensory neurones to induce hyperalgesia, but also 
requires immune cell infiltration. These infiltrating cells are known to release 
algesic mediators, including prostaglandins (Cockeran, Steel et al. 2001) and further 
NGF from the cell or from resident mast cells. Indeed, blockade of neutrophils 
prevents NGF-induced hyperalgesia in rats (Bennett, al-Rashed et al. 1998). 
 
There are 2 receptors for NGF, high affinity tyrosine kinase (TrkA) and common 
neurotrophin (p75NTR). Nerve sensitisation by NGF is thought to be largely 
dependent on TrkA as NGF can still induce thermal hyperalgesia in p75NTR
-/-
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mice. However, neutralising antibodies to p75NTR blocks CFA-induced 
hyperalgesia (Watanabe, Ito et al. 2008), suggesting further studies are required to 
fully understand the role of NGF receptors in hyperalgesia. NGF signalling via 
TrkA results in phosphorylation of TRPV1 and sodium channels such as tetrodoxin-
resistant (TTX-R), potentially through PI3K and MEK/ERK intracellular signalling 
cascades. NGF induced thermal hyperalgesia is thought to be dependent on the 
phosphorylation of TRPV1, indeed, TRPV1
-/- 
mice are insensitive to NGF induced 
thermal induced hyperalgesia. 
 
Prostaglandins are lipid compounds that act on prostanoid receptor subtypes in 
DRG neurons (Huang, Zhang et al. 2006). Prostaglandins are synthesised in 
response to noxious stimuli and inflammation (Ito, Okuda-Ashitaka et al. 2001) by 
COX-1 and COX-2 (induced by cytokines and other inflammatory stimuli) (Kidd 
and Urban 2001) from various cell types including  neutrophils (Cockeran, Steel et 
al. 2001). Prostaglandins  are important in hyperalgesia as they sensitise nociceptors 
by lowering their activation threshold of TRPV1 (Huang, Zhang et al. 2006) and 
TTX-R via cAMP and kinase induction. (England, Bevan et al. 1996).  
 
1.6.2 Immune cells 
 
There has been an increasing focus in rodent models lately on the importance of 
cellular infiltration in the genesis of inflammatory hyperalgesia. These cells release 
key mediators of pain, including prostaglandins and NGF.  
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Neutrophils are the most abundant immune cells, accounting for around 55-70% of 
all white blood cells, and are the dominant cell type in sites of inflammation in the 
first hours following infection or injury. Blockade of neutrophil migration using a 
polysaccharide selectin inhibitor (fucoidan) abolishes cytokine induced hyperalgesia 
(Cunha, Verri et al. 2008). Neutrophils have been shown to release NGF and 
prostaglandins (Cockeran, Steel et al. 2001; Foster, Wicks et al. 2002), which act to 
sensitise the nociceptive system. Neutrophils also produce lipooxygenase (LOX) 
metabolites, some of which can directly act as an agonist on TRPV1. Furthermore, 
inhibition of LOX using nordihydroguaretic acid (NDGA) in murine CFA arthritis 
diminishes hyperalgesia (Szabo, Helyes et al. 2005). Neutrophils are recruited to 
sites of inflammation via chemokines (KC, GRO) released at the site of 
inflammation due to their induction by proinflammatory cytokines.  Blockade of 
these cytokines prevents neutrophil migration (Cunha, Verri et al. 2008). 
 
Macrophages are implicated in the inflammatory hyperalgesia, through the release 
of proinflammatory cytokines and prostaglandins. Macrophage infiltration into the 
DRG follows CFA-injection, and also occurs during AIA (Inglis, Nissim et al. 
2005; Boettger, Hensellek et al. 2008; Segond von Banchet, Boettger et al. 2009). 
Anti-TNF therapy in rats following CFA injection reduces macrophage infiltration 
into the DRG, which correlates with a reduction in mechanical allodynia (Boettger, 
Hensellek et al. 2008). Macrophage infiltration is dependent of TNF through up-
regulation of vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells 
(Schaible, von Banchet et al. 2010). Infiltrating cells during neuropathic models are 
associated with nerve injury. However, this infiltration during AIA is not associated 
with nerve damage, potentially revealing a novel mechanism for macrophages in 
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inflammatory pain states in the absence of neuropathy (Segond von Banchet, 
Boettger et al. 2009; Inglis 2010). 
 
1.6.3 Cytokines  
 
Cytokines are small secreted proteins that regulate cell response over a short range 
and are vital for maintaining inflammation. Cytokines can be divided into pro-
inflammatory (including tumour necrosis factor-α (TNF), interleukin- (IL) -1ß, IL-
17 and IL-6) or anti-inflammatory (including IL-10 and IL-4) depending on their 
action (Sommer and Kress 2004). Cytokines are produced by a number of immune 
cell types including lymphocytes, macrophages and neutrophils. After tissue 
damage, pro-inflammatory cytokines are released at the site from injured cells and 
act to induce a cascade of cytokine and chemokine production, which amplify the 
inflammatory response. The role of pro-inflammatory cytokines in inflammatory 
pain has been addressed in several animal models of arthritis. The focus has largely 
been on TNF due to its well established importance in RA pathology and the 
clinical success of anti-TNF therapies (Inglis 2010).  
 
Injection of TNF into the footpad produces a dose-dependent, rapid mechanical and 
thermal hyperalgesia. This acute action of TNF is transient, returning mechanical 
threshold to normal within 24h (Woolf, Allchorne et al. 1997; Cunha, Verri et al. 
2005). TNF induced pain is largely dependent on prostaglandin release (Cunha, 
Verri et al. 2008) but there is some evidence that TNF can sensitise the sensory 
fibres directly. Application of TNF will induce nerve discharge in a proportion of C 
fibres after 2 minutes (Sorkin, Xiao et al. 1997).  In injured nerves (neuropathic 
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pain), TNF is transported retrograde into the dorsal horn and anterograde to the 
peripheral injury site (Shubayev and Myers 2001). TNF receptors TNFR1 and 
TNFR2 are present in the DRG (Schafers, Sorkin et al. 2003; Schafers, Sommer et 
al. 2008), although their exact locations within the DRG cell types are not fully 
elucidated. To understand any direct mechanism of TNF on sensory nerves, the 
expression of the receptors must be addressed as there are other non-neuronal cell 
types in the DRG that TNF could be acting on. 
 
TNF is also important in models of sustained inflammatory pain. TNF is 
upregulated in the footpad after injection with CFA or carrageenan, and during CIA.  
Blockade of TNF is analgesic in CFA arthritis (Inglis, Nissim et al. 2005), CIA 
(Inglis, Notley et al. 2007) and AIA (Boettger, Hensellek et al. 2008), and 
carrageenan induced hyperalgesia is prevented in TNFR1 deficient mice (Cunha, 
Verri et al. 2005). TNF is an established mediator of inflammatory pain however the 
precise mechanisms controlling this are unclear. It is also unknown whether all 
other pro-inflammatory cytokines are instrumental in inducing hyperalgesia.  
 
1.7 IL-17 
 
1.7.1 Origin , cellular distribution and function 
 
Murine IL-17 was first cloned in 1993 from a T cell hybridoma (Rouvier, Luciani et 
al. 1993) and the human form was first characterised in 1995 (Yao, Fanslow et al. 
1995; Yao, Painter et al. 1995). The structure of IL-17 has been identified as a 
disulphide linked homodimer consisting of 155 amino acids with a molecular mass 
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of 35 kDa (Yao, Painter et al. 1995; Fossiez, Djossou et al. 1996). The crystal 
structure of IL-17 adopts a cystine knot similar to another family member, IL-17F 
(Gerhardt, Abbott et al. 2009). IL-17R has no homology to any other receptors 
outside the IL-17 family. Following cloning of IL-17 and its receptor, a further five 
proteins and four receptors were re-labelled due to sequence homology (Moseley, 
Haudenschild et al. 2003). 
 
The cellular distribution of IL-17 is primarily in but not exclusive to T cells (CD4+, 
CD8+ and γδ T cells) (Korn, Bettelli et al. 2009). IL-17 has also been detected in 
other cell types namely eosinophils (Molet, Hamid et al. 2001), neutrophils 
(Ferretti, Bonneau et al. 2003), NKT cells (Coquet, Chakravarti et al. 2008), 
astrocytes (Meeuwsen, Persoon-Deen et al. 2003) and microglia (Kawanokuchi, 
Shimizu et al. 2007) but the main source of IL-17 remains the memory CD4+ T cell.  
 
IL-17 is a pro-inflammatory cytokine affecting a variety of cell types in 
inflammatory responses. By inducing and working in synergy with TNF-α and IL-
1β, IL-17 increases local inflammation and the expression of other pro-
inflammatory cytokines. IL-17 has therefore been implicated in a range of auto-
immune diseases governed by cytokine production including inflammatory bowel 
disease, psoriasis and RA (Fossiez, Djossou et al. 1996; Chabaud, Durand et al. 
1999; Kikly, Liu et al. 2006; Ouyang, Kolls et al. 2008; Korn, Bettelli et al. 2009) 
(Hwang, Kim et al. 2004). 
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1.7.2 IL-17 Signalling 
 
IL-17 induced signalling is through its receptor IL-17R (Figure 1.8). Initially, IL-
17R was thought to be a single receptor for IL-17, but now it is largely agreed that 
IL-17R is made up of two functional receptors for IL-17 in a heterodimeric complex 
(Toy, Kugler et al. 2006) (Gaffen 2009). This complex consists of receptor subunits 
IL-17RA and IL-17RC.  
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IL-17RC was first described as a receptor for the closely related (≈55%)  IL-17 
homolog IL-17F (Toy, Kugler et al. 2006), but functional studies labelled IL-17RC 
as imperative for IL-17 signalling (Zrioual, Toh et al. 2008; Hu, Ota et al. 2010). 
Interestingly, the affinity for each subunit by IL-17 or IL-17F differs from mice to 
humans. In humans, IL-17RA binds to IL-17 with high affinity but only weakly to 
IL-17F. IL-17RC, thought binds IL-17 and IL-17F with equal affinity. Conversely, 
murine IL-17RA binds IL-17 and IL-17F equally but IL-17RC binds preferentially 
to IL-17F. As IL-17RC binds IL-17F with high affinity in both humans and mice it 
has been suggested that IL-17F signalling through this complex could modulate IL-
17 signalling (Ho and Gaffen 2010). Although murine IL-17RC is required for IL-
17 dependent responses during infection and experimental autoimmune 
encephalomyelitis (EAE) (Hu, Ota et al. 2010), IL-17 can induce signals in murine 
T cells that are thought to lack IL-17RC (Ho and Gaffen 2010) . With the precise 
nature of IL-17 signalling and its receptor unknown, it is difficult to assess how 
exactly IL-17 exerts its effects.  
 
   
What is known regarding the IL-17/IL-17R signalling pathway is that both subunits 
contain SEFIR domains (Maitra, Shen et al. 2007; Ho, Shen et al. 2010). IL-17RA 
engages this SEFIR domain containing ACT1 to promote downstream signalling. 
ACT1 is involved in the activation of NF-κB, necessary for induction of most genes 
by IL-17 (Chang, Park et al. 2006). ACT1 links IL-17R to TRAF6, an adaptor 
molecule used to transduce the signal to activate NF-κB and kinase pathways 
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(Gaffen 2009; Iyoda, Shibata et al. 2010; Roussel, Houle et al. 2010). ACT1 is 
therefore important in IL-17 signalling, but may not act alone. ACT1-/- cells 
stimulated with IL-17 have activated extracellular signal-related kinases (ERK) 
(Qian, Liu et al. 2007), suggesting IL-17R has additional novel signalling pathways 
that require further attention. 
  
 
1.7.3 Th17 Cell Differentiation and Transcription Factors 
 
Upon antigenic stimulation and cytokine signalling, naive T cell differentiate into T 
helper cell subsets (Crome, Wang et al. 2010). T helper cells have traditionally been 
split into either Th1 or Th2 subsets depending on the cytokine profile produced by 
the cell (Furuzawa-Carballeda, Vargas-Rojas et al. 2007). The mediators driving 
Th1/Th2 cells are different depending on cell type. Th1 cell differentiation is reliant 
on IL-12 for differentiation and T-bet transcription factor for linage specific 
cytokines, whilst Th2 cells require IL-4 for differentiation and GATA-3 
transcription factor for linage specific cytokines. Th1 cells are implicated in 
pathogen clearance and autoimmunity, whilst Th2 cells are associated with host 
defence against parasitic infections as well as allergy (Bi, Liu et al. 2007; Weaver, 
Hatton et al. 2007; Korn, Bettelli et al. 2009; Lee, Mukasa et al. 2009). A recent 
addition to the T helper cell family are Th17 cells which produce cytokines distinct 
from Th1/2 subsets (Harrington, Hatton et al. 2005) (Bettelli, Carrier et al. 2006). 
Th17 cells express IL-17, IL-17F, IL-22, IL-21, IL-26, and TNF (Korn, Bettelli et 
al. 2009; Lubberts 2010). Th17 differentiation requires IL-6 and TGF-β initially, 
followed by IL-23 for development and survival (Langrish, Chen et al. 2005; 
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Bettelli, Carrier et al. 2006; Mangan, Harrington et al. 2006) as depicted in Figure 
1.5.  
 
 
                                                                                                                    Chapter 1: Introduction 
 
39 
 
 
IL-23 has been shown to be critical in mediating Th17 responses in CIA (Murphy, 
Langrish et al. 2003), thereby making the IL-23/IL-17 axis a proposed therapeutic 
target (Iwakura and Ishigame 2006; Kikly, Liu et al. 2006; Yago, Nanke et al. 
2007). IL-21 has been suggested as an additional factor in murine and human Th17 
differentiation in the absence of IL-6, although this is subject to some debate 
(Deenick and Tangye 2007; Coquet, Chakravarti et al. 2008). The transcription 
factor RORγt is selectively expressed by murine Th17 cells and IL-17 positive T 
cells (e.g. γδ T cells) (Ivanov, McKenzie et al. 2006). It has been suggested that IL-
17 production is dependent on RORγt as mice deficient in RORγt have much 
reduced IL-17 producing cells (Korn, Bettelli et al. 2009; Littman and Rudensky). 
Human Th17 cells express the human orthologue of RORγt, RORC2 (Annunziato, 
Cosmi et al. 2007; Wilson, Boniface et al. 2007). Overexpression of RORC2 
elevates expression of IL-17, IL-17F and IL-26, key cytokines in the Th17 subset 
(Crome, Wang et al. 2009).  
 
 
1.7.4 IL-17 in RA 
 
IL-17 was first implicated in RA when its addition to RA synoviocytes was found to 
elevate IL-6 and IL-8 production (Fossiez, Djossou et al. 1996; Miossec 2007). IL-
17 was then shown to be important for neutrophil infiltration via the induction of 
IL-8 (Laan, Cui et al. 1999). The presence of bioactive IL-17 in vitro in RA 
synovial membrane cultures and synovial fluid further associated it with the disease, 
although serum levels are minimal (Chabaud, Durand et al. 1999; Kotake, Udagawa 
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et al. 1999).  IL-17 was implicated as a mediator of joint pathology as by 
administering it in vitro osteoclast (bone absorbing cells key for bone erosion) 
differentiation from bone marrow cells was provoked (Kotake, Udagawa et al. 
1999). This was supported by showing that repeated intra-articular injection of IL-
17 facilitated joint inflammation, cartilage proteoglycan loss and bone erosion in 
mice (Lubberts, van den Bersselaar et al. 2003; Lubberts, Koenders et al. 2005). 
Through the use of animal models of arthritis, blockade of IL-17 was found to be 
therapeutic and prevent joint erosion (Lubberts, Koenders et al. 2004; Koenders, 
Lubberts et al. 2005).  In addition, mice deficient in IL-17 have reduced severity of 
CIA (Nakae, Nambu et al. 2003).   
 
Through the upregulation of inflammatory mediators and chemoattractants, IL-17 
drives many of the cellular processes that cause the tissue damage and inflammation 
associated with RA (Figure 1.6). T cells infiltrating into the arthritic joint provide 
the main source of IL-17, where it acts on synoviocytes and macrophages to 
produce and synergise with IL-6, IL-1β, and TNF-α to maintain inflammation. IL-
17 facilitates cartilage damage by acting on chondrocytes to induce nitric oxide 
(NO) which prevents matrix synthesis, and on macrophages to release matrix 
metalloproteinases (MMPs) (Koshy, Henderson et al. 2002). Accumulation of 
neutrophils increases cartilage loss through release of proteolytic enzymes 
(Kowanko, Bates et al. 1989) and respiratory burst. The interaction between IL-17 
and osteoblasts results in RANKL, a protein necessary for osteoclastogenesis, 
which leads to bone erosion. IL-17 induced acute  joint inflammation and cartilage 
destruction is dependent on TNF (Lubberts, Joosten et al. 2001), but there is little 
known about IL-17 being independent of TNF during arthritis (Koenders, Lubberts 
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et al. 2006). Dissecting the relationship between TNF and IL-17 during acute and 
arthritic conditions is therefore critical when considering IL-17 as a therapeutic 
target. IL-17 blockade as a therapy is now being assessed in the clinic, although this 
is largely based on animal studies and the efficacy of anti-IL-17 treatment in human 
RA is currently unknown (Genovese, Van den Bosch et al. 2010). 
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1.7.5 IL-17 and Pain 
 
  As IL-17 is implicated in RA pathology, new studies are emerging to 
understand what role IL-17 has in inflammatory pain. Recently, IL-17 was shown to 
be involved in mBSA AIA hyperalgesia. Blockade of IL-17 in this model reduced 
mechanical hypernociception. In addition, immune cells also played a role as, with 
IL-17 induced neutrophil migration into the knee joint, and prevention of this 
cellular infiltration diminishing hypernociception (Pinto, Cunha et al. 2010). 
However, this is the only study currently published; therefore this thesis aims to 
identify further the role of IL-17 in inflammatory hyperalgesia. 
 
 
1.8  Hypothesis 
 
 The hypothesis of this study is that IL-17 through induction of 
inflammatory proteins, mediates inflammatory hyperalgesia in the periphery. As IL-
17 is known to induce TNF, it could be that IL-17 acts upstream of TNF, initiating 
an inflammatory cascade leading to peripheral sensitisation.  
 
It is established that IL-17 is an important target in CIA, but through the 
enhancement of peripheral sensitisation, it is hypothesised that IL-17 blockade 
would be also beneficial in treating chronic pain. By decreasing IL-17 induced 
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release of pro-inflammatory cytokines at the site of inflammation, there would be a 
reduction in nerve sensitisation. 
 
1.9  Aims of study 
 
  The overall aims of this study are to understand if IL-17 plays a role in 
mediating inflammatory hyperalgesia both in acute and chronic settings. This will 
be achieved as follows; 
 
1. IL-17 will be investigated in acute pain through injection into the murine footpad. 
 
2. The relationship between IL-17 and TNF will be examined in the same setting to 
see if IL-17 is acting independently of TNF. 
 
3. To examine the importance of IL-17 during chronic pain, an anti-IL-17 therapy will 
be administered to mice with CIA to assess efficacy in both disease modification 
and hyperalgesia. Gene expression changes are known to be important in the 
generation of peripheral and central sensitisation and this will be assessed in the 
periphery (joint and DRG) and the spinal cord. 
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2.1 Animal models  
Adult male C57BL/6, TNFR1
-/-
 or TNFR2
-/-
 aged 10-12 weeks were used for all 
acute experiments. C56BL/6 mice have been used previously in studies of IL-17 
mediated hyperalgesia, making the strain an appropriate choice. TNFR1-/- and 
TNFR2-/- mice were maintained on a C57BL/6 background. DBA/1 (classical CIA 
strain) or C57BL/6 mice ages 10-12 weeks were used for all CIA experiments. Mice 
were housed in groups of 5 (C57BL/6) or 8 (DBA/1) and maintained at a 
temperature of 21 ± 2°C (mean ± SEM) on a 12-hour light/dark cycle (7:00 AM to 
7:00 PM), with food and water available ad libitum. All experimental procedures 
were approved by the UK Home Office and Ethical Review Process Committee and 
followed guidelines issued by the International Association for the Study of Pain.  
 
2.1.1 Acute hyperalgesia model 
 
Animals were either given an intra-plantar injection (10µl) of rTNF, rIL-17 
(PeproTech EC Ltd, London) or vehicle (PBS +1% mouse plasma) into the right 
hind paw, the concentration being described in Chapter 3. All injections were 
performed by Kay McNamee, the exception being the initial pilot study conducted 
by Kay McNamee and Julia Inglis. Fucoidan at 20mg/kg (as described (Cunha, 
Verri et al. 2008) in 100µl of PBS (Sigma-Alridge) was administered 2h prior to 
injection with recombinant cytokines in order to prevent leukocyte infiltration. Anti-
TNF polyclonal antibody was raised in rabbits in-house by a previous group and 
serum IgG purified using Protein G (Melon Gel Pierce), performed by Kay 
McNamee. In both behaviour examinations, animals were subjected to each test the 
day prior to study and 1, 3, 6, 18 and 24h post injection. 
                                                                                       Chapter 2: Materials and Methods 
46 
 
 
 
2.1.2 Air pouch model 
 
The air pouch model of leukocyte infiltration allows for easy retrieval of migrated 
cells and the exudates can be used to detect proteins secreted in the pouch. Air 
pouches were raised on the back of mice by subcutaneous injection of 5 mls air on 
day 0, followed by 1ml on day 4. On day 5, 50 ng of rIL-17, rTNF or PBS vehicle 
in 100μl was injected into the pouch. 4hrs post injection, the animals were 
sacrificed and 2ml of PBS was injected into the pouch. After massaging the pouch 
to ensure efficient cell retrieval, the liquid was re-drawn and the cells pelleted by 
centrifugation. The cells were then resuspended in fresh PBS to be counted and the 
supernatant collected for measurement of cytokines by ELISA. All experiments 
were conducted by Kay McNamee. 
 
2.1.3 Collagen-induced Arthritis model 
 
The CIA model has been previously described as a model of hyperalgesia and so 
was utilised in investigating analgesic effects of IL-17 blockade in a chronic setting.  
Mice were immunized by subcutaneous injection at 2 sites at the base of the tail 
with 100 μl of bovine (DBA/1 mice) or chicken (C57BL/6 require chicken collagen 
due to bovine collagen being insufficient to induce disease) type II collagen (4 
mg/ml) emulsified in Freund’s complete adjuvant (CFA) (BD Biosciences, Oxford, 
UK). For the method of isolating collagen, see 2.4. Arthritis developed in the mice 
14–28 days after immunization. The clinical score of the arthritic mice was 
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determined with a maximum of 3 for each paw, with a maximum score of 12 per 
mouse. The criteria for each score were as follows; 0= normal, 1= slight swelling 
and/or erythema, 2= pronounced swelling, 3= ankylosis. The hind paw swelling was 
measured using calipers. Clinical score and paw swelling measurements were taken 
for a total of 10 days post onset. Treatment of C57BL/6 mice was carried out with 
anti-IL-17 (a kind gift from Paula Sardinha at UCB CellTech UK). Anti-IL-17 
treatment was by administering 2mg/ml of drug in 100μl sterile PBS intra-
peritoneally on the day of disease onset and day 3, 5, 7 and 10 post onset.   
Immunisation of the mice was conducted by Kay McNamee, Dany Perocheau and 
Saba Alzabin, and clinical score was largely measured by Kay McNamee, with 
assistance from Saba Alzabin and Dany Perocheau. 
 
 
2.2 Behavioural tests 
 
To investigate the involvement of cytokine in the generation of inflammatory 
hyperalgesia, appropriate tests must be used to detect enhanced pain responses. 
Animals with hyperalgesia will react more quickly to a heat stimulus, and elicit a 
withdrawal response with less mechanical force than a naive counterpart. In 
addition, if there is pain on only one side of the body, the subject will exert more 
pressure on their unaffected side. Evoked pain and spontaneous behaviour were 
measured in both the acute and CIA studies. Briefly, thermal hyperalgesia was 
assessed using the Hargreaves plantar apparatus and mechanical nociception was 
determined using Von Frey filaments. The Hargreaves and Linton tests were utilised 
in the acute studies. Both the Hargreaves and Von Frey tests were performed at day 
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1, 3, 7 and 10 post onset in arthritic, anti-IL-17 treated mice, and age-matched naive 
controls. LABORAS was only performed day 10 post onset of arthritis. 
 
 
2.2.1 Hargreaves  
 
Nociceptive thresholds to thermal stimulation were measured using the Hargreaves 
test (Ugo Basile, Varese, Italy) in both the acute and chronic studies. Animals were 
placed in a Perspex box and an increasing heat source was applied to the plantar 
surface of the injected hind paw. The time before the paw was lifted was measured. 
Care was taken to take only one or two measurements to prevent sensitisation of the 
paw from repeated tests. Naive animals registered with a time of 8-12 seconds 
before paw withdrawal, while animals with hyperalgesia recorded times between 1-
4 seconds before lifting the paw. All tests conducted by Kay McNamee.  
 
 
2.2.2 Linton incapacitance tester 
 
Differential distribution of weight was measured using the Linton incapacitance 
tester in the acute studies. The Linton incapacitance tester is not suitable for CIA 
measurements as it relies on a change in only one side, where as the CIA model 
affects multiple limbs. Animals were placed into the Linton with their hind paws on 
two separate sensors, each measuring weight in grams. The difference between the 
left (uninjected) and right (injected) was calculated as a percentage. A 100% value 
indicates equal weight distribution, where as a value of 70% or lower suggests 
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leaning to the uninjected side. All tests using the Linton were conducted by Kay 
McNamee with early support from Julia Inglis. 
 
2.2.3 Von Frey  
 
Nociceptive thresholds to mechanical stimuli in the CIA/chronic studies were 
measured using Von Frey filaments. The filaments are of increasing gauge (0.6-6g) 
and by depressing the filament under the arthritic paw until bending point it yields a 
consistent force to the footpad.  Using the Dixon up/down method, the lowest gauge 
of filament consistently eliciting a rapid withdrawal by the mouse (at least 3 times) 
was considered to be the nociceptive threshold. All use of Von Frey filaments were 
conducted by Kay McNamee. 
 
2.2.4 LABORAS 
 
LABORAS (Laboratory Animal Behaviour Observation Registration and Analysis 
System) (Metris B.V. The Netherlands) is a non-invasive technique designed to 
quantify normal behaviour in rodents (Inglis, Notley et al. 2007; Inglis, McNamee 
et al. 2008). Each animal is placed into a separate cage linked to a platform that 
detects motion by vibration. Each vibration is then translated to a particular 
spontaneous behaviour. C56BL/6 mice from three groups were tested over an 18h 
period for changes in locomotion, immobility, climbing and grooming. The three 
groups consisted of mice with CIA at 10 days post onset, mice with CIA at 10 days 
post onset with anti-IL-17 treatment, and age-matched naive controls. To account 
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for any cage differences, each group was measured equally between all the 
LABORAS cages. All use and analysis of LABORAS was done by Kay McNamee. 
 
 
2.3 Cell culture 
 
2.3.1 NIH 3T3 murine fibroblasts 
 
The murine fibroblast cell line NIH 3T3 was obtained from the ATTC repository. 
Cells were grown in DMEM containing 10% FBS (PAA) and 100 U/ml 
penicillin/100μg/ml streptomycin to 60-80% confluency in a 10 cm tissue culture 
dish. Cells were detached by incubation with prewarmed EDTA/Trypsin (PAA) at 
37°C, 5% CO2 for 5 m, before washing and re-plating 1:4 in fresh medium.  
 
2.3.2 Stimulation of NIH 3T3 cells with TNF or IL-17 
 
Cells were seeded at 5 x 10
3
 cells/well in a 96 well flat-bottomed tissue culture plate 
and left to adhere over-night at 37°C and 5% CO2. Cells were stimulated in 
complete medium with 10ng/ml of cytokine. To test TNF blockade, cells were pre-
treated overnight with anti-TNF antibody at 10μg/ml. Before stimulation the cells 
were washed to remove any unbound antibody in the cell supernatant. The cells 
were then stimulated with cytokine as before. The conditioned medium was 
harvested over a 24h time course and stored at -70°C prior to chemokine/cytokine 
determination by ELISA.  
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2.4 Collagen 
 
Type II collagen was prepared from either chicken carcasses or bovine joints as 
described previously (Miller 1972; Herbage, Bouillet et al. 1977; Williams, 
Williams et al. 1992; Inglis, Simelyte et al. 2008).  
 
Cartilage was powdered using a liquid nitrogen freezer mill (Spex, UK).  
Proteoglycans were then removed by adding 5 volumes of 4M guanidine-HCL in 
0.05M Tris (pH 7.5) and left to stir overnight at 4°C. Insoluble material was 
removed by centrifugation (12,000 rpm) and washed twice in 0.5M acetic acid. The 
pellet was then resuspended in 20 volumes of 0.5M acetic acid, and pH adjusted to 
2.8 using 70% formic acid. 1g of pepsin was added to the solution for every 20g of 
cartilage (original wet weight) and was left stirring at 4°C for 48h, then centrifuged 
(12,000 rpm) and the supernatant retained. 
 
 NaCl was added to the supernatant remaining from Step 3 resulting in a 0.9M 
solution to precipitate dissolved type II collagen. The solution was centrifuged 
(12,000 rpm), then redissolved in 0.05M Tris plus 0.5M NaCl (pH 7.5) and left 
stirring overnight at 4°C. The solution was then centrifuged and the pellet re-
suspended in 100ml 0.1M acetic acid and dialysed again Na2PO4 (pH 9.4) to 
inactivate residual pepsin. 
 
 The collagen was spun down (12,000 rpm) and re-suspended in 100ml 0.5M 
acetic acid. The final product was dialysed extensively against 5l acetic acid (0.5M) 
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then freeze-dried and stored in a desiccator at 4°C. For immunisation, freeze-dried 
collagen was dissolved in 0.1M acetic acid at 4mg/ml overnight at 4°C. Collagen 
was produced by the Richard Williams group, including assistance by Kay 
McNamee. 
 
2.5 ELISAS 
Murine ELISA kits for TNF (BD Biosciences Cat. No 558874), KC (R+D Systems 
Cat. No. DY453) and IL-6 (BD Biosciences) were utilised according to the 
manufacturer’s instructions.  
 
2.6 Genotyping 
 
DNA was isolated from tail tips or ear clips of transgenic mice using Sigma 
Genotyping kit (Sigma). Genotyping transgenic mice was carried out using primers 
for TNFR1 and conducted by Kay McNamee and Dany Perocheau. 
(5’-GGATTGTCACGGTGCCGTTGAAG-3’Fwd 
5’CCTTTACGGCTTCCCAGAATTACC-3’Rev) (Marshall, Toh et al. 2004) 
or TNFR2  
(5’-CCTCTCATGCTGTCCCGGAAT-3’Fwd  
5’-AGCTCCAGGCACAAGGGCGGG-3’ Rev) respectively. (Balasa, Van Gunst et 
al. 2000) 
The PCR conditions were as follows; 
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Step 1: 95°C for 5 minutes 
Step 2: 95°C for 30 seconds 
Step 3: 60°C for 45 seconds     Repeat for 29 cycles 
Step 4: 72°C for 60 seconds 
 
PCR products were visualised on a 1% agarose gel with ethidium bromide at 488 
base pairs for TNFR1 and 200 base pairs for TNFR2. 
 
2.7 Histology 
 
Paws were fixed in 10% formalin and sent to the Charing Cross Hospital (London, 
UK) for processing. Paw sections were decalcified, and then paraffin embedded and 
cut using a cryostat by David Essex (Histology). Sections were then stained with 
haematoxylin and eosin (H+E) and visualised at 20 x magnification. Photographs 
were taken by Kay McNamee and Julia Inglis. 
 
2.8 Myeloperoxidase assay 
 
Neutrophil infiltration into the plantar tissue was assessed by histology and a
 
kinetic-colorimetric assay for myeloperoxidase (MPO). The protocol was adapted 
from previous studies (Cunha, Verri et al. 2008). Paws were broken up using a bio-
pulveriser (Stratech Scientific LTD, UK) and liquid nitrogen. The powder was then 
homogenised in 50 mM K2HPO4
 
buffer (pH 6.0) containing 0.5% hexadecyl 
trimethylammonium
 
bromide (HTAB) (Sigma-Alridge).
 
The tissue was centrifuged
 
at 13,000 g for 10 min and the pellet discarded. To prepare the solution
 
for analysis, 
                                                                                       Chapter 2: Materials and Methods 
54 
 
50µl of the supernatant was mixed with 50
 
µl 50 mM phosphate buffer, pH 6.0, and 
tetramethylbenzidine (TMB) substrate was added to detect the MPO. MPO activity 
was calculated by each plate being measured every minute for 5 minutes at 450nm. 
The change in absorbance each minute was averaged, with a change of 1 in 
absorbance equal to 1 unit of MPO activity (McNamee, Burleigh et al. 2010).The 
protocol was optimised by Kay McNamee who performed all experiments and 
analysis. 
 
 
2.9 RNA isolation and cDNA generation from murine tissues 
 
Julia Inglis extracted the tissue for the DBA CIA experiments and Kay McNamee 
isolated all tissue for the C57BL/6 CIA study. Kay McNamee processed all tissue 
samples from both studies for RNA isolation and conducted all real-time PCR and 
analysis.  
 
It is often difficult to adequately quantify a range of cytokines and their receptors in 
a disease model. This is due to several factors; recovery of good quality material 
can be low and time consuming depending on the tissue type, and the tissue may 
require additional stimulation to detect cytokines even in an inflammatory 
environment. Detecting cytokine protein concentration uses a large amount of 
tissue, limiting the amount of cytokines that can be investigated.  Real-time PCR  
using cDNA can amplify product from a single cell, making it ideal when tissue is 
limiting as for joint, spinal cord and the DRG. 
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Total RNA was extracted from various tissues. Mice were sacrificed and perfused 
with saline. Hind paws from naive mice, arthritic mice (day 10 post onset) and anti-
IL-17 treated arthritic mice (day 10 post onset) were snap frozen in liquid nitrogen. 
The frozen paws were then homogenised using a bio pulveriser and liquid nitrogen, 
and the resulting powder ground on resin (GE Healthcare) in RLT lysis buffer 
(QIAGEN) with 2M DTT. The lysate was spun down on the resin and the 
supernatant added to a QIAshredder column for further homogenisation. The RNA 
extraction was then continued using the RNeasy RNA isolation kit (QIAGEN) 
according to the manufacturer’s protocols.  
 
DRG’s and the lumbar region of the spinal cord were stored in RNA later 
(QIAGEN) until processing. Samples were taken from the RNA later and pulverised 
on ceramic beads with RLT lysis buffer in a Precellys™ Control Device for soft 
tissue homogenisation. The RNA was extracted from supernatant using the RNeasy 
kit (QIAGEN).  
 
Reverse transcription (RT) was performed on RNA from all tissues using an ABI 
High Capacity Kit (Applied Biosystems) according to the manufacturer’s 
instructions. The RT master mix for each reaction contained; 
 
 
 
4.0μl 10X RT Buffer 
1.6μl 25X dNTP Mix (100mM) 
4.0μl 10X RT Random Primers 
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2.0μl MultiScribe™ Reverse Transcriptase  
2.0μl RNase Inhibitor 
6.4μl Nuclease-free H20 
 
The total reaction volume was 20μl master mix with an equal volume of RNA. The 
reaction was then reverse transcribed using a thermocycler under the following 
conditions; 
 
Step 1: 25°C for 10 mins 
Step 2: 37°C for 120 mins 
Step 3: 85°C for 5 mins 
Step 4: 4°C ∞ 
The cDNA was diluted to 120 μl with Nuclease-free H20 prior to real-time PCR. 
 
2.10 Real-time quantitative PCR 
 
Quantitative real-time PCR was performed on a Corbett Lifesciences Rotorgene 
6000 thermocycler (Corbett Lifesciences, Sydney) or ABI AB7900HT 384 platform 
system (Applied Biosystems). PCR was performed using a two-step amplification 
method as detailed here; 
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Step 1: 95 °C for 10 mins 
Step 2: 95 °C for 2 seconds  
Step 3: 60 °C for 20 seconds  
 
The concentration of each target gene was calculated using the ΔΔCt method and 
expressed as relative units using a naive sample as a calibrator (arbitrary unit 1) 
after normalizing against HPRT. All primers used were purchased from the ABI 
Taqman inventory. Details of individual primers used are below. 
 
HPRT: Mm00446968_m1 
IL-17: Mm00439619_m1 
TNF: Mm99999068_m1 
IL-1: Mm00434228_m1 
IL-6: Mm00446190_m1 
IL-10: Mm00439616_m1 
IL-17RA: Mm00434214_m1 
IL-17RC: Mm00661861_m1 
TNFR1: Mm00441875_m1 
TNFR2: Mm00441889_m1 
GFAP: Mm00546086_m1 
 
2.11 Statistical analysis 
All statistical analysis was performed using Graphpad Prism software (Version 
5.02). For all experiments involving more than two groups, a one-way ANOVA test 
was used with Dunnett’s post test to the naive or vehicle controls. For two groups of 
Repeat for 45 cycles 
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animals, a paired t-test was used when assessing differences in opposing paws of the 
same mice (i.e. comparing contralateral and ipsilateral limbs). For two groups of 
different mice (i.e. naive vs arthritic) an unpaired t-test was performed. 
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CHAPTER 3 
IL-17 INDUCES HYPERALGESIA 
VIA TNF DEPENDENT 
NEUTROPHIL INFILTRATION 
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3.1 Introduction 
 
Cytokines are known to be important in inflammatory pain as shown by extensive 
studies using TNF (Cunha, Poole et al. 1992; Woolf, Allchorne et al. 1997; Cunha, 
Verri et al. 2005). Injection of TNF into the hindpaw of rodents induces 
hyperalgesia by 1h post injection, persisting for up to 6h but returning to naive 
levels within 24h (Woolf, Allchorne et al. 1997). This hyperalgesia has been found 
to coincide with neutrophil migration, and these neutrophils are vital for 
hyperalgesia to occur (Cunha, Verri et al. 2008). TNF hindpaw injection also 
triggers release of IL-1 and KC which is attenuated with TNF blockade (Cunha, 
Verri et al. 2005). Pre-treatment with anti-NGF prevents TNF and IL-1 induced 
hyperalgesia (Woolf, Allchorne et al. 1997). This finding lead to the hypothesis that 
TNF provokes enhanced pain through the induction of an inflammatory cascade, 
ending in the release of NGF and other agents (e.g. PGE2). These mediators 
sensitise sensory nerves, resulting in hyperalgesia. 
 
TNF has been widely acknowledged as an important target for RA therapy (Maini, 
Elliott et al. 1995), but TNF blockade is also analgesic in animal models of arthritis 
and acute inflammatory pain (Inglis, Notley et al. 2007; Boettger 2008). Although 
anti-TNF has been very successful in treating RA, not all patients respond, creating 
a need to investigate other targets. There have also been suggestions of rapid 
analgesia in anti-TNF responders, provoking further examination of cytokines in 
pain.  
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IL-17 is a pro-inflammatory cytokine largely produced by activated T cells as well 
as neutrophils (Ferretti, Bonneau et al. 2003), NKT cells (Coquet, Chakravarti et al. 
2008) and astrocytes (Meeuwsen, Persoon-Deen et al. 2003). IL-17 can induce TNF 
and synergises with TNF, IL-1, and IL-6 to maintain inflammation (Chabaud, Page 
et al. 2001; Hwang, Kim et al. 2004). IL-17 is also a potent chemotactic agent for 
leukocytes through its induction of chemokines (Laan, Cui et al. 1999; Witowski, 
Pawlaczyk et al. 2000). IL-17 is implicated in RA as it is increased in the synovium 
and synovial fluid of RA patients (Chabaud, Durand et al. 1999; Kotake, Udagawa 
et al. 1999). However, like other T cell cytokines, the level of IL-17 in RA synovial 
culture is very low and its blockade has modest effects in vitro (Hillyer, Larche et 
al. 2009). Clinical trials of drugs targeting IL-17 are in the early stages. Blockade of 
IL-17 reduces clinical score, paw swelling and joint destruction in animal models of 
arthritis (Nakae, Nambu et al. 2003; Lubberts, Koenders et al. 2004; Koenders, 
Lubberts et al. 2005; Rohn, Jennings et al. 2006). Based on these observations, IL-
17 has potentially a major role in the pathogenesis of RA; though any contribution 
from IL-17 in inflammatory pain has received limited attention (Pinto, Cunha et al. 
2009).  
 
The overall objective of this first chapter is therefore to investigate the role of IL-17 
in the generation of acute inflammatory pain. 
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3.2 Aims of chapter 
 
The aims of this chapter were to address the question of whether IL-17 induces 
hyperalgesia in naive C57BL/6 mice and to investigate the relationship with TNF. 
These aims were achieved as follows: 
 
1. IL-17 was administered into the hind paw of naive C57BL/6 mice and then 
thermal hyperalgesia and weight bearing were assessed and compared to the effect 
of TNF administration. 
 
2. IL-17 dependency on TNF was investigated by a) IL-17 injection into wild type 
mice treated with anti-TNF antibody and b), IL-17 injection into TNFR
-/-
 or TNFR2
-
/-
mice. 
 
3. The importance of neutrophil migration in cytokine-induced hyperalgesia was 
assessed by blockade of selectins required for leukocyte infiltration. 
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3.3 Results 
 
3.3.1 TNF and IL-17 paw swelling response.  
 
Before IL-17 could be investigated in an arthritic model of chronic pain, it was first 
established whether a single injection of the cytokine could induce acute pain in 
naïve mice. TNF is known to induce acute pain and so this was used as a positive 
control. C57BL/6 mice were injected with 10, 20 or 50 ng of rTNF or rIL-17. The 
negative control was the vehicle (PBS with 1% mouse plasma).  
 
The mice were assessed for paw swelling pre injection and 1h, 3h, 6h and 24h after 
injection (Figure 3.1). Paw swelling was measured using calipers with only the 50 
ng dose in both rTNF and rIL-17 treated mice showing definite paw swelling, 
although there was clear redness in both groups at the 20 ng dose showing that there 
was inflammation but it was not enough to cause overt swelling. In all experiments 
the swelling returned to levels comparable to the vehicle control within 24h. As 20 
ng of rTNF or rIL-17 could induce pain and leaning in the mice without significant 
swelling, this was the dose used for all further experiments. 
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3.3.2 IL-17 and TNF induce hyperalgesia and neutrophil migration. 
 
Initially, IL-17 was investigated for its ability to induce hyperalgesia and weight 
distribution change. TNF having previously been shown to induce hyperalgesia was 
injected as a positive control. Animals received a 10μl intraplantar injection of 20ng 
rTNF, 20ng rIL-17, or vehicle (PBS with 1% mouse plasma) and were assessed for 
thermal hyperalgesia and weight bearing prior to injection and 1h, 3h, 6h, and 24h 
after injection (Figure 3.2a/b). 
 
TNF induced thermal hyperalgesia as early as 1h with IL-17 injected mice showing 
hyperalgesia 3h post injection. At 6h both TNF and IL-17 treated mice were leaning 
significantly onto their uninjected paw signifying pain. As IL-17 induced thermal 
hyperalgesia was delayed in comparison to TNF, this raised the possibility that IL-
17 was causing pain indirectly through the generation of another mediator. 
 
Next the question of whether TNF and IL-17 induced hyperalgesia was dependent 
on the inflammatory response was addressed. Although TNF and IL-17 were 
injected at doses that did not induce significant paw swelling, the possibility of sub-
clinical inflammatory changes could not be discounted. Both TNF and IL-17 have 
been shown to induce neutrophil migration, and this would be the main population 
of migrating cells to the site of inflammation in this time period. Hence, MPO 
activity was assayed throughout the 24h period. MPO is produced by activated 
neutrophils and is an accepted marker of neutrophil migration (Cunha, Verri et al. 
2008). It was found that MPO activity increased in parallel to TNF and IL-17 
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induced hyperalgesia, both being significant at 3h (Figure 4d). To further assess the 
neutrophil infiltration, animals were injected with TNF or IL-17 as before and at 3h 
post injection paws were fixed for histology and stained with haematoxylin and 
eosin (H+E) (Figure 3.2c). The presence of neutrophils was observed in the TNF 
and IL-17 injected mice but not vehicle control at 3h post injection. This shows that 
there is a direct association between neutrophil migration and cytokine induced 
hyperalgesia. 
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3.3.3 IL-17 induced hyperalgesia and neutrophil migration is dependent on TNF. 
 
IL-17 is a known inducer of TNF, therefore the extent to which IL-17 
administration led to hyperalgesia via the production of TNF was investigated. 
Animals were injected with IL-17, TNF, or vehicle as described above, with or 
without 2μg of polyclonal anti-TNF IgG purified antibody. Thermal hyperalgesia 
and weight distribution change were again measured over a 24h period. There was 
no hyperalgesia or weight bearing changes in anti-TNF treated mice injected with 
either TNF or IL-17 (Figure 3.3a/b), indicating that IL-17 induced hyperalgesia is 
dependent on TNF. 
 
As it had been shown that cytokine induced hyperalgesia correlated with MPO 
activity, MPO activity at 3h post injection was again examined by comparing anti-
TNF treated mice with controls. As shown in Figure 3.3c, neither TNF nor IL-17 
injected mice treated with anti-TNF had significant MPO activity at 3h post 
injection. This demonstrates that IL-17 induced neutrophil migration is dependent 
on TNF. 
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3.3.4 TNFR1 but not TNFR2 is imperative for IL-17 induced hyperalgesia and 
neutrophil migration. 
 
Having established that IL-17 acts via TNF, it was investigated which of the two 
TNF receptors (TNFR1 or TNFR2) was mediating hyperalgesia. 
In order to assess differential receptor effects during hyperalgesia, TNFR1
-/-
 mice 
and TNFR2
-/-
 mice were injected with IL-17, TNF or vehicle as described above. 
Thermal hyperalgesia and weight distribution change were again measured over a 
24h period. In TNFR2
-/-
 mice, both TNF (Figure 3.4a) and IL-17 (Figure 3.4b) 
induced hyperalgesia comparable to that observed in wild type mice. However, 
there was no hyperalgesia or weight bearing change in TNFR1
-/-
 mice after either 
TNF (Figure 3.4d) or IL-17 administration (Figure 3.4e). This data shows that IL-17 
and TNF induced hyperalgesia is dependent on TNF binding to TNFR1 but not to 
TNFR2. 
 
As TNF and IL-17 induced hyperalgesia were found to be dependent on TNFR1, it 
was examined whether neutrophil migration was similarly regulated. MPO activity 
at 3h post injection was assessed, comparing TNF and IL-17 injected wild type 
mice with TNF and IL-17 injected TNFR1 or TNFR2 mice. TNFR2
-/-
 mice showed 
increased neutrophil migration following cytokine injection, comparable to that of 
wild type controls (Figure 3.4c). In contrast, there was no significant neutrophil 
infiltration in TNFR1
-/-
 mice treated with either TNF or IL-17 (Figure 3.4f), 
demonstrating that neutrophil migration is also dependent on TNF binding to 
TNFR1.  
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3.3.5 IL-17 induced hyperalgesia is dependent on neutrophil migration 
 
Recent studies have suggested that neutrophils make an important contribution to 
hyperalgesia, and previous experiments showed that cytokines such as TNF (Cunha, 
Verri et al. 2008) and NGF (Bennett, al-Rashed et al. 1998) induce hyperalgesia in 
rodents only when neutrophils are present. Therefore, it was investigated whether 
blockade of neutrophil migration would prevent hyperalgesia in IL-17 treated mice. 
 
Mice were pre-treated with 20mg/kg fucoidan (a competitive inhibitor of selectins 
needed for neutrophil migration) i.p. 2h prior to injection with either TNF or IL-17. 
The hyperalgesia and weight bearing change was examined as described in Chapter 
2. A proportion of the mice were killed and their paws taken 3h post injection with 
either cytokine to confirm neutrophil blockade by MPO activity assay. In TNF or 
IL-17 mice pre-treated with fucoidan, there was neither hyperalgesia (Figure 3.5a) 
nor weight distribution changes (Figure 3.5b), nor significant MPO activity (Figure 
3.5c). These data confirm that neutrophil migration is required for cytokine induced 
hyperalgesia. 
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3.4 Discussion 
 
 In this chapter, it has been shown that IL-17 induces hyperalgesia. IL-17 induced 
hyperalgesia is however indirect as it is dependent on TNF binding to TNFR1. In 
addition it is clear that neutrophil recruitment is required for cytokine induced 
hyperalgesia and is also dependent on TNF.  
 
In agreement with previous studies, TNF induced transient changes in weight 
bearing and thermal hyperalgesia, peaking between 3-6h after injection and 
returning to normal responses by 24h. IL-17 also induced hyperalgesia and weight 
bearing changes. However, there was a delay in IL-17 induced hyperalgesia relative 
to TNF induced hyperalgesia. This delay in the IL-17 treated mice suggested that 
this cytokine was inducing hyperalgesia indirectly through the induction of another 
mediator (e.g. TNF). It has been shown previously that macrophages stimulated 
with IL-17 produce TNF after a delay of 3h (Jovanovic, Di Battista et al. 1998), 
which is comparable to the delay in IL-17 induced pain in this initial study.   
 
IL-17R is expressed on resident TNF producing cell types such as endothelial cells, 
resident macrophages and fibroblasts, therefore IL-17 could potentially induce TNF 
from any of these cells. IL-17 is known to synergise with TNF in the production of 
other cytokines and chemokines such as IL-6 and IL-8 (Fossiez, Djossou et al. 
1996; Hartupee, Liu et al. 2007). Despite this synergistic relationship between IL-17 
and TNF, the dependency of IL-17 on TNF is largely unknown. However, a 
previous study showed that IL-17 induced joint inflammation in naive mice but was 
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dependent on TNF as cell infiltration into the joint was prevented in IL-17 injected 
TNF deficient mice (Koenders, Lubberts et al. 2006). TNF signals through two 
receptors, TNFR1 and TNFR2. Previous studies suggest that TNF induced 
hyperalgesia is dependent on binding TNFR1 in a chronic constriction injury (CCI) 
model of neuropathic pain. Thus, neutralisation of TNFR1 reduces thermal 
hyperalgesia and mechanical allodynia whereas neutralisation of TNFR2 has no 
effect. In addition, in a methylated BSA (mBSA) mouse model, IL-17 mediated 
hyperalgesia is reduced in TNFR1
-/-
 mice and with TNF blockade (Pinto, Cunha et 
al. 2009). In this study, even a single injection of IL-17 in a healthy mouse elicits 
hyperalgesia for up to 6h. Both IL-17 and TNF induced hyperalgesia is absent in 
TNFR1
-/-
 mice but present in TNFR2
-/-
 mice. These findings clearly show that both 
TNF and IL-17 induced hyperalgesia is dependent on TNF signalling via TNFR1. 
These data are the first to show divergent roles for TNF receptors in inflammatory 
hyperalgesia.  
 
 
Recently there has been an increasing focus on the importance of cellular infiltration 
in the genesis of cytokine induced hyperalgesia. Neutrophils are the most abundant 
immune cells, accounting for 55-70% of all white blood cells, and are the dominant 
cell type in sites of inflammation in the first hours following infection or tissue 
damage. Neutrophils account for 90% of the cells in the arthritic synovial fluid 
(Wright, Moots et al. ; Hilliquin, Dulioust et al. 1995) and release proteases and 
cytokines leading to further tissue damage. After TNF injection there is a rapid 
accumulation of neutrophils in to the hind paw, and these neutrophils are required 
for hyperalgesia to occur (Cunha, Verri et al. 2008; Pinto, Cunha et al. 2009). As 
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IL-17 is chemotactic for neutrophils via the induction of chemokines, the 
contribution of neutrophils to IL-17 induced hyperalgesia was investigated. Firstly, 
TNF and IL-17 induced neutrophil migration to the hind paw by histology and MPO 
activity assay was confirmed. Both IL-17 and TNF injected mice had a significant 
increase in MPO activity which correlated with hyperalgesia. The elevated pain 
response and elevated MPO activity returned to naive control levels concurrently. 
These parallel time courses suggested that neutrophil migration was linked to TNF 
and IL-17 induced hyperalgesia.  
This link was further investigated to show that neutrophil migration was prevented 
in mice treated with anti-TNF and TNFR1
-/-
 mice but not TNFR2
-/-
 mice, revealing 
a novel finding that IL-17 is dependent on TNF binding to TNFR1 to induce 
neutrophil migration as well as hyperalgesia.  
 
 This data shows a positive correlation between neutrophil recruitment and 
hyperalgesia. Indeed, neither IL-17 nor TNF injected mice pre-treated with fucoidan 
(to block neutrophil migration) developed hyperalgesia, confirming the necessity of 
neutrophil migration for cytokine induced pain. This experiment supports recent 
studies showing that fucoidan prevents TNF induced hyperalgesia and IL-17 
mediated mechanical hypernociception respectively (Cunha, Verri et al. 2008; 
Pinto, Cunha et al. 2009). In the TNF study, fucoidan was also found to only 
prevent neutrophil rolling and not to reduce the level of TNF induced pro-
inflammatory cytokines in the plantar tissue. This suggests that neutrophil induced 
hyperalgesia is not achieved through the further production of TNF. Neutrophils 
have been shown to release NGF and prostaglandins, both of which directly 
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sensitise nociceptors. Further studies are needed to identify the exact mechanisms 
by which neutrophils cause hyperalgesia in this system. 
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CHAPTER 4 
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4.1 Introduction 
 
 
As demonstrated in the previous chapter, neutrophil migration is required for TNF 
and IL-17 induced inflammatory hyperalgesia to occur in mice. Neutrophils are 
generated in the bone marrow and on maturing are released into the circulation 
(Bainton, Ullyot et al. 1971; Berkow and Dodson 1986). Neutrophils then remain in 
the blood unless they are mobilised and recruited to a site of inflammation by 
following a chemical gradient in a process known as chemotaxis. This gradient is 
governed by chemokines locally produced at the site of inflammation (Zigmond 
1974; Wilkinson 1990; Baggiolini 1998).  
 
IL-17 has long been established as a mediator of neutrophil infiltration. In one 
study, conditioned media from IL-17 stimulated human endothelial cells added to a 
transwell migration assay significantly increased neutrophil chemotaxis in an IL-8 
dependent manner (Laan, Cui et al. 1999). In a peritoneal cavity model, IL-17 
administration was found to recruit neutrophils via production of the chemokine 
GROα (Witowski, Pawlaczyk et al. 2000). IL-17 has been shown to elicit airway 
neutrophil infiltration in vitro by increasing adhesion molecules on endothelial cells, 
thereby enhancing leukocyte progression to sites of inflammation (Roussel, Houle 
et al. 2010). Injection of IL-17 into the knee joint of mice resulted in neutrophil 
migration and this was dependent on TNF (Lemos, Grespan et al. 2009). However, 
assessing the production of chemokines in this model can be difficult as the knee 
joint will only yield a small amount of exudate (in the range 1-3μl) and cells. 
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The air pouch model of leukocyte infiltration allows for easy retrieval of migrated 
cells and the exudates can be used to detect proteins secreted in the pouch. 
Traditionally zymosan is used to stimulate chemokines and provoke cellular 
infiltration but recently cytokines have been used for more specific studies. TNF 
injection into the air pouch model facilitates neutrophil infiltration by increasing 
expression of chemokines KC and MIP-2 (Tessier, Naccache et al. 1997; Clish, 
O'Brien et al. 1999). In addition, blockade of MIP-2 and KC significantly reduces 
leukocyte recruitment induced by TNF (Tessier, Naccache et al. 1997).  
 
The previous chapter has suggested that IL-17 induced hyperalgesia is dependent on 
neutrophil infiltration mediated by TNF/TNFR1 signalling. Therefore, it was 
necessary to validate and further explore IL-17 dependency on TNF in the context 
of neutrophil migration.  
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4.2 Aims of chapter 
 
 
The aims of this chapter were to confirm IL-17 dependency on TNF for neutrophil 
migration, and understand further the mechanism by which this occurs. This aim 
was achieved as follows; 
 
1. IL-17 was injected into air pouches in wild type mice to ascertain that it was 
sufficient to induce neutrophil migration 
2. IL-17 was injected into air pouches in TNFR1-/- or TNFR2-/- mice to assess TNF 
dependency 
3. Air pouch exudates were analysed for secretion of KC and levels compared with 
numbers of neutrophils found in each experiment 
4. A fibroblast cell line was stimulated with IL-17 to investigate if IL-17 could induce 
KC and whether this production was dependent on TNF 
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4.3 Results 
 
4.3.1 IL-17 and TNF induce neutrophil migration 
 
Having demonstrated that IL-17 and TNF induced hyperalgesia was dependent on 
neutrophil migration the mechanism needed to be examined more thoroughly. It was 
hypothesised that IL-17 was inducing TNF from resident cells and in turn TNF was 
inducing chemokines from the same cells to attract neutrophils. To investigate this, 
an air-pouch animal model was used. Firstly, it was determined that administration 
of IL-17 or TNF (50 ng) into the pouch would elicit neutrophil infiltration. After 4 
hours, the mice were sacrificed and the cells in the pouch washed out with PBS 
(Figure 4.1a). The cells were then pelleted, counted using a haemocytometer and 
trypan blue exclusion, and the supernatant from the pelleted cells collected for 
chemokine/cytokine detection by ELISA.  Injection of IL-17 or TNF into the air 
pouch induced significantly higher numbers of cells when compared with vehicle 
injected mice at 4h post injection. 
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4.3.2 IL-17 induced neutrophil migration is dependent on TNFR1 but not TNFR2 
 
To validate the divergent roles for TNF receptors and IL-17 dependency on TNF, 
TNFR1
-/- 
and TNFR2
-/-
 mice were injected with IL-17 or TNF (Figure 4.1a). In the 
TNFR2
-/-
 mice neutrophil migration was increased compared to WT mice, 
suggesting an inhibitory role for TNFR2. IL-17 induced neutrophil migration was 
dependent on TNF binding to TNFR1, which is in agreement with the acute 
hyperalgesia study in Chapter 3.  
 
4.3.3 IL-17 induced KC is dependent on TNFR1 but not TNFR2 in a model of 
leukocyte migration 
 
As neutrophils migrate to the site of inflammation by following a chemokine 
gradient, we next investigated whether TNF induced chemokines from resident cells 
in the pouch. After migrated cells were washed out of the pouch and spun down, the 
supernatant was removed and used in an ELISA for KC, the murine homolog of IL-
8 (Figure 4.1b). Both IL-17 and TNF injected pouches had significantly elevated 
KC expression compared to the TNFR1
-/-
 mice, in which KC secretion had largely 
been prevented. In the TNFR2
-/-
 mice there was a reduction in the amount of KC 
when compared to the wild type controls but KC production in TNFR2
-/-
 was still 
significant when compared to the TNFR1
-/-
 mice. 
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4.3.4 IL-17 induced KC from a fibroblast cell line is dependent on TNF 
 
To investigate the role of IL-17 in neutrophil migration, the cells producing TNF 
and KC must be considered. Fibroblasts along with macrophages are major resident 
cells in the air-pouch (and the footpad), but assaying cytokines produced by these 
cells requires extensive ex vivo tissue culture. Alternatively, the tissue can be 
paraffin embedded and sectioned for IHC, but many antibodies are ineffective in 
paraffin fixed tissue.  
 
To rapidly assess induction of inflammatory mediators by cytokines, a 3T3 
fibroblast murine cell line was cultured and stimulated with either IL-17 or TNF. To 
determine the amount of cytokine to be used, fibroblasts were stimulated with a 
range of concentrations from 5-100ng/ml (Figure 4.2). IL-6 had been shown to be 
elevated previously with either TNF or IL-17 stimulation, therefore detection of this 
cytokine by ELISA was used as a control to determine the concentration of cytokine 
to be used in further experiments. At 24h post-stimulation, both TNF and IL-17 at 
concentrations between 10-100ng/ml had induced IL-6 in the supernatant. As 
cytokine expression is generally low in vivo, it was decided that the lowest dose 
with clear IL-6 up-regulation would be used. At 5ng/ml TNF had increased IL-6 but 
IL-17 did not, therefore a dose of 10ng/ml were both cytokines had clear up-
regulated IL-6 was used for all experiments. 
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To determine if KC was produced by fibroblasts, 3T3 fibroblasts were stimulated 
with TNF or IL-17 at 10ng/ml and KC in the supernatant was measured by ELISA 
over a 24h period (Figure 4.3). TNF induced significant KC levels by 1h post 
stimulation, while KC elevation significant in IL-17 treated cells at 3h post 
stimulation. IL-17 KC production was significantly reduced when the fibroblasts 
were pre-treated with anti-TNF, supporting previous data in this thesis that IL-17 
actions in an acute setting are dependent on TNF. 
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4.4 Discussion 
Data shown previously has suggested that IL-17 induced neutrophil migration is 
dependent on TNF. This finding was verified here in the air pouch model of cell 
migration whereby TNF and IL-17 induced neutrophil migration after 4h in wild 
type mice. In addition, in TNFR1
-/-
 mice, neutrophil migration was abolished 
supporting the earlier investigation.  
It is well established that IL-17 is important for neutrophil infiltration into sites of 
inflammation through induction of chemokines. Human neutrophils migrate towards 
16HBE cells stimulated with IL-17 within 20 min, but this infiltration is abolished 
with anti-IL-8 treatment (Laan, Lotvall et al. 2001). IL-17 increased neutrophil 
numbers in rat bronchoalveolar lavage (BAL) fluid is prevented by anti-MIP-2 
therapy. In a peritoneal cavity cell infiltration model, IL-17 stimulation yields a 
significant number of neutrophils by 2h post stimulation, peaking at 4h. This is 
preceded by highly increased levels of KC, and reduced with KC neutralisation 
(Laan, Cui et al. 1999). IL-17 stimulates chemokine expression from a variety of 
cell types. These include human IL-8 from transformed human bronchial epithelial 
cells (Laan, Cui et al. 1999) and rheumatoid synovial fibroblasts (Hwang, Kim et al. 
2004), MIP-2α from murine mesothelial cells (Witowski, Pawlaczyk et al. 2000), 
and KC from mouse embryo fibroblasts (Hartupee, Liu et al. 2007). In addition, IL-
17RA
-/-
 mice have a reduced basal level of MIP-2α and impaired neutrophil 
recruitment after challenge with K. pneumonia (Ye, Rodriguez et al. 2001). It has 
been suggested previously that IL-17 mediated neutrophil migration is dependent on 
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TNF (Koenders, Lubberts et al. 2006; Lemos, Grespan et al. 2009). The latter study 
showed that IL-17 induced chemotaxis depended on CXC chemokines. However, it 
was unknown whether IL-17 is dependent on TNF to stimulate the initial release of 
these chemokines. 
As neutrophil migration requires chemokine secretion, KC expression in the air 
pouch was quantified here. A KC ELISA using the pouch exudates revealed that IL-
17 and TNF treated wild type and TNFR2
-/-
 mice had significantly higher KC 
expression than the TNFR1
-/- 
mice where KC expression was prevented. Thus, it 
was concluded that TNFR2 is not required for neutrophil migration. It has been 
shown previously that IL-17 mediated neutrophil infiltration is dependent on TNF 
(Lemos, Grespan et al. 2009). However, this data is the first to suggest that IL-17 
acts specifically via TNF/TNFR1 to induce KC for neutrophil migration. 
 
In both the acute hyperalgesia study and the air pouch study the major resident cells 
were fibroblasts and macrophages. KC is expressed in a number of cell types 
including fibroblasts; therefore TNF and IL-17 induction of KC from fibroblasts 
was investigated using a 3T3 cell line. By 3h, both TNF and IL-17 had induced a 
significant amount of KC. However, when the cells were pre treated with anti-TNF, 
KC expression was reduced in both the TNF and IL-17 stimulated cells. This 
suggests that IL-17 induces neutrophil migration by inducing TNF, which in turn 
induces KC from the fibroblasts to allow neutrophil migration. To support this 
hypothesis, IL-17 is known to induce release of TNF from macrophages and these 
cells are also resident in the footpad and the airpouch. Therefore this chapter 
suggests that IL-17 induces TNF from resident cells (macrophages/fibroblasts) 
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which results in KC production. Neutrophils then infiltrate the site of inflammation, 
expressing other algesic mediators that more directly sensitise the nerve, leading to 
hyperalgesia (Figure 4.4). Indeed, NGF is known to be produced by neutrophils and 
blockade of neutrophils prevents NGF induced hyperalgesia (Bennett, al-Rashed et 
al. 1998). 
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5.1 Introduction 
 
 
The previous chapters have shown that IL-17 can induce hyperalgesia via induction 
of neutrophil migration but that this is dependent on TNF. However, these studies 
have been in healthy mice in short-term, acute experiments where the enhanced pain 
desists within 24h. Cytokine injection alone therefore, does not represent the 
complexity of chronic pain and inflammation during arthritis.   
 
RA is characterised by inflammation of the joints, proliferation of the synovial 
lining layer, leukocyte infiltration, pannus formation, and joint destruction. A 
number of animal models are used to mimic aspects of RA pathology to understand 
the disease and develop novel targeted therapies. The most widely used model is 
CIA which elicits a polyarthritis 14-28 days post-immunisation with bovine or 
chicken collagen. CIA involves synovitis, immune cell infiltration into the joint, 
pannus formation, cartilage erosion, joint destruction and loss of function. Indeed, 
TNF blockade was shown to be a highly effective treatment for CIA, facilitating its 
transfer to the clinic. In addition, both RA patients and CIA mice have underlying 
chronic pain, making this model ideal to investigate new drugs for disease 
modification and analgesia. 
 
Pro-inflammatory cytokines are accepted as being important in the pathogenesis of 
RA and CIA. Expression levels of these proteins in the arthritic joint are determined 
to ascertain whether their kinetics change during arthritis. Increased amounts of pro-
inflammatory cytokines during CIA can indicate novel targets for therapy.  
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The central nervous system (CNS) is known to produce proinflammatory cytokines 
during adjuvant-induced arthritis (AIA) (Bao, Zhu et al. 2001). Astrocytes in the 
spinal cord are known to be activated during CIA, potentially driving central 
sensitisation, thereby maintaining chronic hyperalgesia (Inglis, Notley et al. 2007). 
Activated astrocytes and microglia are known to produce pro-inflammatory 
cytokines, including TNF and IL-17 in vitro (Meeuwsen, Persoon-Deen et al. 2003; 
Kawanokuchi, Shimizu et al. 2007) but it is unknown whether these cells express 
cytokines during CIA.  IL-17 is present in RA synovium and synovial fluid and IL-
17 blockade ameliorates CIA. However, any potential role IL-17 and its receptor 
have in the PNS and CNS (DRG and spinal cord/brain respectively) during CIA is 
unknown. This chapter addresses the kinetics of IL-17/IL-17RA expression in key 
tissues in the nociceptive pathway (joint, DRG, spinal cord) during CIA in DBA/1 
mice. 
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5.2 Aims of chapter 
 
 
The aim of this chapter was to understand kinetics of cytokine expression during 
CIA in key tissues of the nociceptive pathway. This aim was achieved as follows; 
 
Tissues from DBA/1 mice with CIA were taken and expression of cytokine and 
their receptor mRNA was determined by quantitative real-time PCR to examine 
whether changes in mRNA were apparent during arthritis. 
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5.3 Results 
 
5.3.1 IL-17, TNF, IL-1 and IL-6 are upregulated in the joints of mice with CIA. 
In order to investigate IL-17 kinetics during CIA, it was first established whether 
IL-17 message was expressed in the joint and whether this expression changed 
during arthritis. DBA/1 mice with CIA were sacrificed day 10 post onset of disease 
and arthritic paws analysed for IL-17 mRNA using quantitative real-time PCR. 
When compared to naive age-matched controls, IL-17 mRNA was significantly 
increased in the joints of mice with CIA. TNF, IL-1 and IL-6 expression were also 
compared as these cytokines had been shown to be up regulated in previous 
investigations. TNF was significantly upregulated and IL-6 and IL-1 were also 
highly increased in the CIA joint. 
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5.3.2 TNF receptors and IL-17 receptors are differently expressed in the joints 
of mice with CIA. Both IL-17 and TNF mRNA were significantly upregulated in 
the CIA joint, and as previous investigations had shown divergent roles for TNFR1 
and TNFR2 during acute conditions, it was important to assess the kinetics of the 
receptors for each cytokine receptor in the CIA joint. TNFR1 message was not 
significantly different from the naive group but TNFR2 was upregulated. IL-17RA 
message also increased in the CIA joint.  
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5.3.3 IL-17RA, TNFR1 and 2 are up regulated in the L4/L5 DRGs of mice with 
CIA. As there was increased expression in the CIA joint of both IL-17 and TNF, it 
was considered whether either cytokine could have a more direct influence on the 
nervous system during CIA. Therefore the DRGs (L4/L5) innervating the joint were 
investigated for expression of their respective receptors IL-17RA, TNFR1 and 
TNFR2. All three receptors had significantly elevated expression during CIA. 
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5.3.4 TNF and IL-1 but not IL-6 or IL-17 is upregulated in the spinal cords of 
mice with CIA. Glia and microglial cells are known to produce TNF, IL-1, IL-6 
and IL-17 when activated, however expression of these cytokines in the CNS have 
never been investigated during murine CIA. To address this, the lumbar region of 
the spinal cords were analysed for TNF, IL-1, IL-17 and IL-6 message and 
expression compared to levels in naive controls. TNF (Figure 5.4a) and IL-1 (Figure 
5.4b) were significantly up-regulated. IL-6, although present was comparable to the 
naive control (Figure 5.4c). IL-17 message was detectable but too poorly expressed 
in the tissue to be quantified. 
 
 
5.3.5 GFAP is upregulated in the spinal cords of mice with CIA. Earlier 
investigations have shown that astrocytes produce pro-inflammatory cytokines 
when activated, so as TNF and IL-1 were upregulated in CIA, it was necessary to 
look for markers of astrocyte activation.  GFAP is a marker for astrocyte activation 
and it was observed that GFAP was significantly increased in the spinal cord during 
CIA (Figure 5.4d), indicating astrocyte activation, which is in agreement with 
previous findings using an IHC approach (Inglis, Notley et al. 2007).  
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5.3.6 TNFR1/2 and IL-17RA are upregulated in the spinal cords of mice with 
CIA. Expression of TNFR1 and 2 was analysed in spinal cords of CIA mice and 
found to be significantly increased over the naive control receptor levels (Figure 
5.5a and b). IL-17RA was also upregulated (Figure 5.5c), despite unquantifiable 
expression of IL-17A. 
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Discussion 
 
This chapter has shown that cytokines and their receptors expressed in nociceptive 
tissues undergo distinct changes during arthritis. By day 10 post onset of arthritis, 
pro-inflammatory cytokines are elevated in the joint, and TNF and IL-17 receptors 
are upregulated in the DRG innervating the arthritic joint. For the first time it has 
been shown that TNF and IL-1 are elevated in the spinal cord during CIA and that 
the expression of TNF and IL-17 receptors also increases. A potential role for 
astrocytes in CIA has also been indicated by increased expression of their activation 
marker during arthritis. 
 
It is often difficult to adequately quantify a range of cytokines and their receptors in 
a disease model. This is due to several factors; recovery of good quality material 
can be low and time consuming depending on the tissue type, and the tissue may 
require additional stimulation to detect cytokines even in an inflammatory 
environment. Detecting cytokine protein concentration uses a large amount of 
tissue, limiting the amount of cytokines that can be investigated.  By extracting 
RNA from the tissue, mRNA can be transcribed into complementary DNA (cDNA) 
and the cytokine gene detected using specific primers and real-time PCR. Real-time 
PCR can amplify product from a single cell, making it ideal when tissue is limiting 
as for joint, spinal cord and the DRG. 
  
Enhanced production of pro-inflammatory cytokines has long been associated with 
RA. This elevation has also been shown in the joints of rodents during experimental 
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arthritis with protein levels correlating with mRNA expression levels (Rioja, Bush 
et al. 2004; Pohlers, Siegling et al. 2005). TNF, IL-1 and IL-6 expressing cells 
progressively increase between day 1 and 10 post onset of disease (Marinova-
Mutafchieva, Williams et al. 1997). TNF, IL-1, IL-6 and IL-17 increases in message 
correlate with increased disease severity (Ferrari-Lacraz, Zanelli et al. 2004). The 
significantly enhanced message for TNF, IL-17, IL-6 and IL-1 demonstrated here 
therefore concurs with earlier investigations.  
 
As previous chapters focussed on TNF and IL-17, receptors for each cytokine were 
examined in the CIA joint. IL-17RA and TNFR2 were significantly upregulated; 
however, TNFR1 expression was not different from naive controls. TNFR1 is 
expressed on most cell types (Kollias, Douni et al. 1999) and considered to be 
imperative for most inflammatory actions of TNF (MacEwan 2002). Indeed, it has 
been reported that TNF acting through TNFR1 is critical for arthritis to occur in 
animal models (Mori, Iselin et al. 1996; Arntz, Geurts et al. 2010), although there is 
opposing literature which suggests that arthritis incidence is unaffected by TNFR1 
deficiency (Tada, Ho et al. 2001; Williams-Skipp, Raman et al. 2009). In addition, a 
novel immunoregulatory role for TNF has been described which appears to be 
dependent on TNFR1. TNF inhibits p40 which regulates Th1/Th17 populations in 
the lymph nodes during CIA. However, this inhibition of p40 is lost in TNFR1
-/-
 
mice, resulting in expansion if Th1/Th17 cells (Notley, Inglis et al. 2008). Here 
expression of TNFR1 was not significantly increased, potentially due to the 
ubiquitous expression of TNFR1. Alternatively, TNFR1 is down regulated in late 
arthritis possibly to limit duration of tissue inflammation. To answer this, kinetics of 
the receptor must be assessed in a time course of CIA. Unlike TNFR1, the 
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expression of TNFR2 is limited to cells of haemopoetic origin endothelial origin 
(Kollias, Douni et al. 1999). During CIA, immune cells infiltrate the affected joints 
which could account for the increased expression of this receptor. TNFR2 has been 
linked with a more protective role for TNF, due to its expression on highly 
suppressive Tregs (Chen, Subleski et al. 2008) and exacerbation of experimental 
colitis in mice lacking TNFR2+ T cells (Dayer Schneider, Seibold et al. 2009). To 
investigate any protective role for TNFR2 during CIA, TNFR2
-/-
 mice should be 
compared to wild-type mice for disease susceptibility and progression. IL-17RA, 
like TNFR1 is ubiquitously expressed, and its enhanced expression here could be 
due to infiltrating cells. However, IL-17RA is a subunit of the IL-17R signalling 
complex, therefore expression of IL-17RC in the CIA joint must be considered to 
fully understand the action of IL-17 during late arthritis.  
  
As discussed in Chapter 1, it has been reported that cytokines are present in the 
DRG but expression in this tissue for cytokine receptors is poorly understood. In 
this study, mRNA levels for TNFR1, TNFR2 and IL-17RA were significantly 
increased. Upregulation of TNFR1 and TNFR2 has previously been shown in CFA 
arthritis (Inglis, Nissim et al. 2005) which suggested that TNFR1 was 
predominately expressed in neuronal cells, whilst TNFR2 was expressed by small 
non-neuronal cells in the DRG. IL-17RA in the DRG has not previously been 
shown, and it is unknown where in the PNS it is expressed. Greater expression of 
the receptors could mean a more direct action of the ligands on the DRG during 
CIA, but additional work is required to identify the precise cells involved. 
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Recently, there has been a focus on investigating the role of the CNS in maintaining 
chronic pain states and the central production of cytokines. Astrogliosis is 
associated with chronic pain in CIA detected by an increase in GFAP (Inglis, Notley 
et al. 2007). Here, GFAP is significantly increased, indicating that astrocytes are 
active and central involvement is important in CIA. Microglia are activated in some 
forms of arthritis, but have previously been shown not to be activated during CIA 
(Inglis, Notley et al. 2007). However, as it is unknown whether other cell types 
infiltrate the CNS during CIA, increased expression could also be due to infiltrating 
cells and therefore must be investigated. 
 
Activated astrocytes and microglia are also known to produce TNF, IL-1, IL-6 and 
IL-17 (Benveniste, Sparacio et al. 1990; Chung and Benveniste 1990; Van 
Wagoner, Oh et al. 1999; Meeuwsen, Persoon-Deen et al. 2003). As it has been 
suggested that microglia are not active during CIA, any elevation seen here could be 
localised to astrocytes, depending on CNS infiltrates. TNF, IL-1 and IL-6 are 
known to be upregulated in the AIA spinal cord (Bao, Zhu et al. 2001), but this 
chapter is the first study to show elevation of TNF and IL-1 in the spinal cord 
during CIA. Surprisingly, IL-6 expression did not differ from naive controls. IL-17 
although present, was too low to be quantified. This indicates that IL-6 and IL-17 
are not required at elevated levels in CIA CNS inflammation. TNFR1, TNFR2 and 
IL-17RA were all found to be upregulated in the spinal cord during CIA. It has been 
suggested that TNF receptors have divergent roles in the CNS. TNFR1 is thought to 
aggravate neuronal cell death and induce upregulation of molecules known to be 
important in CNS infiltration by leukocytes (Gimenez, Sim et al. 2004; Marchetti, 
Klein et al. 2004).  Conversely, TNFR2 is considered to be neuroprotective 
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(Marchetti, Klein et al. 2004), but interestingly is thought to be expressed only by 
microglia and not astrocytes (Dopp, Mackenzie-Graham et al. 1997; McCoy and 
Tansey 2008) (although this is subject to controversy (Kuno, Yoshida et al. 2006)). 
As microglia are reported not to be activated during CIA (Inglis, Notley et al. 2007), 
TNFR2 upregulation may indicate an additional route to maintain quiescence via 
TNF, thereby preventing further inflammation and neuronal cell death. Further 
investigations utilising TNFR1
-/-
 or TNFR
-/-
 mice are needed to further elucidate the 
potential paradoxical role of TNF in the CNS during CIA.  As IL-17 is weakly 
expressed here, elevation of the IL-17RA could be due to cellular infiltration.  
However, as IL-17RA is one subunit of the IL-17 receptor, IL-17RC expression 
must therefore be assessed. Further work is required to understand the role of IL-
17RA and IL-17RC during CIA.  
 
This chapter has shown that IL-17 is a potential target in CIA due to its upregulation 
in the joint. The increased expression of IL-17RA in the DRG may point to a more 
direct action for IL-17 in the PNS during CIA. The influence of IL-17 on other 
proinflammatory cytokines in all these tissues can be examined by IL-17 blockade 
during CIA. 
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6.1 Introduction 
 
Anti-IL-17 treatment has been shown to be effective in several animal models of 
arthritis. Neutralising antibodies to IL-17 prevented joint inflammation and bone 
erosion in DBA/1 mice with CIA (Lubberts, Koenders et al. 2004).  Furthermore, 
IL-17 blockade during AIA suppressed joint inflammation and bone erosion by 
potently reducing expression of TNF and IL-1 and RANKL (Koenders, Lubberts et 
al. 2005). However, although the anti-arthritic effects of IL-17 blockade have been 
extensively described, it has never been investigated whether anti-IL-17 therapy can 
also be analgesic.  
 
The CIA model of arthritis has previously been described as a valid model for 
chronic hyperalgesia (Inglis, Notley et al. 2007). Hyperalgesia was tested in CIA 
using the Hargreaves and Von Frey assessments, with both tests revealing a 
reduction in thermal and mechanical thresholds on the day of disease onset. 
Reduced thresholds were maintained up to 18 days (thermal) and 28 days 
(mechanical) post onset of arthritis. Astrogliosis, known to occur during chronic 
pain states, was evident by day 10 post onset. After administration of anti-TNF on 
the day of onset, thermal latency was significantly increased in comparison to 
vehicle treated mice by day 3, with mechanical latency significantly increasing by 
day 7 of arthritis. In addition, astrogliosis was suppressed at day 10 post onset after 
anti-TNF administration. In addition, AIA in the rat knee also results in lowered 
pain thresholds and reduced locomotion. Both etanercept and infliximab attenuated 
hyperalgesia and restored locomotion (Boettger, Hensellek et al. 2008). These 
studies show that anti-TNF treatment is analgesic in animal models of arthritis, as 
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IL-17 is also implicated in RA it is important to address whether IL-17 blockade is 
analgesic as well as therapeutic. As previous chapters have shown that IL-17 is 
dependent on TNF in acute conditions, future experiments need to consider 
dependency of IL-17 on TNF in arthritic conditions, facilitating the need to use 
TNFR1/TNFR2-/- mice. These mice are bred on a C57BL/6 background; therefore 
the initial experiments use C56BL/6 mice for CIA as a more suitable strain 
comparison. 
 
 
6.2 Aims of chapter 
 
The aims of this chapter were to assess CIA in the C57BL/6 mice as a model for 
hyperalgesia and to investigate the efficacy of anti-IL-17 treatment as both 
therapeutic and analgesic. These aims were achieved as follows; 
 
1. C57BL/6 mice were immunised with type II chicken collagen in CFA and on the 
day of disease onset were either treated with anti-IL-17 or left untreated. Disease 
progression and hyperalgesia were monitored in each group over a 10 day period. 
Spontaneous behaviour was assessed on day 10 post onset. 
 
2. On day 10 post onset of disease, animals were culled and tissues were taken and 
examined for changes in cytokine and cytokine receptor expression by real-time 
PCR. 
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6.3 Results 
 
6.3.1 IL-17 blockade suppresses clinical score and paw swelling in CIA. Firstly 
it was necessary to test whether administration of anti-murine IL-17 could suppress 
disease in C57BL/6 mice with CIA.  C57BL/6 mice were immunised with type II 
chicken collagen in CFA as described previously (Inglis, Simelyte et al. 2008). On 
the day of disease onset, 200μg anti-IL-17 polyclonal antibody was injected intra-
peritoneally in 100μl sterile PBS and then every other day until day 10 post onset 
(Figure 6.1). Anti-IL-17 treatment markedly reduced clinical severity and paw 
swelling by day 4 post onset of disease when compared to control mice with CIA. 
This suppression of disease was maintained for the duration of the treatment period.  
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6.3.2 IL-17 blockade reduces thermal and mechanical hyperalgesia in CIA. As 
CIA had been shown to be a model for chronic hyperalgesia in DBA/1 mice, it was 
important to assess hyperalgesia in the milder form of arthritis observed in C57BL/6 
mice. Arthritic and anti-IL-17 treated arthritic mice were examined for thermal and 
mechanical nociception using the Hargreaves and Von Frey evoked pain tests 
(Figure 6.2). On the day of disease onset, and day 3, 7 and day 10 post onset, each 
treated animal had their thermal and mechanical thresholds assessed alongside 
control mice with CIA. By day 7 post onset, both thermal and mechanical 
thresholds had significantly increased when compared with arthritic mice, which 
demonstrated hyperalgesia throughout the course of disease. By day 10 post onset, 
nociception in anti-IL-17 treated mice was comparable to naive mice. 
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6.3.3 IL-17 blockade normalises spontaneous behaviour to that of naive mice.  
 
Arthritis effects spontaneous behaviour in mice with CIA (Inglis, Notley et al. 
2007). In order to investigate whether IL-17 blockade restored change in 
spontaneous behaviour, mice were placed in a LABORAS monitor at day 10 post 
onset (Figure 6.3). Naive and IL-17 treated groups were compared with the CIA 
group. Mice with CIA had significantly reduced climbing and locomotion and 
increased immobility when compared to age-matched naive mice. Grooming 
appeared to be less in mice with CIA, but this was not significant. With anti-IL-17 
administration, locomotion and immobility in the treated arthritic mice had returned 
to naive levels. Climbing in the treated mice increased compared to the CIA group 
but was still significantly less than the naive mice, indicating a partial recovery.  
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 6.3.4 Real-time PCR profile 
 
6.3.4.1 Real-time PCR profile of joints from anti-IL-17 treated and control 
mice with CIA 
 
In order to investigate the effect of anti-IL-17 treatment on other pro-inflammatory 
cytokines in the joints of mice with CIA, hind paws were removed at day 10 post 
onset, snap frozen and RNA isolated for real-time PCR. Real-time PCR was used to 
quantify message expression levels in all tissues due to low tissue yield. Message 
levels of IL-17 (Figure 6.4a), TNF (Figure 6.4b), IL-1 (Figure 6.4c) and IL-6 
(Figure 6.4d) all increased during CIA but were down regulated in anti-IL-17 
treated mice.  
 
IL-17RA was upregulated in mice with CIA (Figure 6.5a) , but reduced with anti-
IL-17 treatment. IL-17RC (Figure 6.5b) in contrast, was down regulated in CIA and 
this reduction was maintained after therapy. TNFR1 (6.5c) was also reduced in 
comparison to naive joints and again TNFR1 message continued to be significantly 
reduced in anti-IL-17 treated mice versus controls. TNFR2 (Figure 6.5d) was 
upregulated during CIA, which is consistent with the results obtained in DBA/1 
mice in Chapter 5. TNFR2 expression was reduced with anti-IL-17 therapy and was 
not significantly different from naive joints.  
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6.3.4.2 Real-time PCR profile of L4/L5 DRGs from anti-IL-17 treated and 
control mice with CIA 
 
As the previous chapter had shown changes in the kinetics of IL-17RA and the TNF 
receptors in DBA/1 mice, it was necessary to validate these findings in the C57BL/6 
mice. L4/L5 DRGs from arthritic and treated mice were removed at day 10 post 
onset and RNA was isolated. All samples were then examined for changes in 
message expression by real-time PCR. As seen in the DBA/1 mice in Chapter 5, IL-
17RA (Figure 6.6a), TNFR1 (Figure 6.6c) and TNFR2 (Figure 6.6d) were 
upregulated in CIA. A novel finding was that IL-17RC (Figure 6.6b) also increased 
during CIA. All these receptors were reduced to naive levels with anti-IL-17 
treatment. 
 
Although it is known that the DRG can produce proinflammatory cytokines, it was 
unknown whether there was expression during CIA. TNF (Figure 6.7a) and IL-1 
(Figure 6.7b) message was significantly increased by day 10 post onset but with IL-
17 blockade were comparable to the expression level in naive mice. IL-6 message 
(Figure 6.7c) did not significantly differ between the groups. IL-17 was only 
detectable in a proportion of the CIA group and therefore could not be quantified. 
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6.3.4.3 Real-time PCR profile of spinal cords from anti-IL-17 treated and 
control mice with CIA 
 
As significant differences in message expression had been shown in cytokine and 
cytokine receptors in the lumbar spinal cord during CIA in DBA/1 mice, any 
changes also needed to be validated in C57BL/6 mice with CIA.  
 
IL-17 was only present in arthritic mice and therefore unquantifiable, a similar 
finding to DBA/1 mice with CIA. TNF (Figure 6.8a), IL-1 (Figure 6.8b) and GFAP 
(Figure 6.8d) message correlated with DBA/1 mice by being upregulated during 
CIA. However, with anti-IL-17 therapy, TNF, IL-1 and GFAP were all comparable 
to naive spinal cords levels. IL-6 expression was also similar to DBA/1 findings, 
with no significant differences in any of the groups (Figure 6.8c). 
 
IL-17RA (Figure 6.9a) and IL-17RC (Figure 6.9b) expression remained unchanged 
in all groups, but TNFR1 (Figure 6.9c) and TNFR2 (Figure 6.9d) expression was 
consistent with DBA/1 mice, as both were upregulated. Anti-IL-17 therapy reduced 
both TNFR1 and TNFR2 to naive levels. 
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6.4 Discussion 
 
This chapter has shown that treating CIA in C57BL/6 mice with neutralising 
antibodies to IL-17 reduces clinical score, paw swelling and hyperalgesia. In 
addition, proinflammatory cytokines increased during CIA in the joint, DRG and 
spinal cord and were potently reduced with anti-IL-17 therapy.  
 
Anti-TNF therapy has been highly successful in treating RA patients. However, not 
all patients respond adequately. This has lead to new investigations into other 
proinflammatory cytokines targets in RA. IL-17 is present in the RA joint and 
blockade of IL-17 is therapeutic in animal models of arthritis (Lubberts, Koenders 
et al. 2004). Here, administration of anti-IL-17 antibodies reduced clinical score and 
paw swelling significantly by day 4 post onset. This is comparable to TNF blockade 
in CIA where paw swelling was significantly reduced in comparison to vehicle 
controls by day 2 post onset and clinical score was reduced by day 5 post onset of 
disease (Williams, Feldmann et al. 1992).  The rapid disease reduction and 
correlation with an established successful biologic show that anti-IL-17 is a valid 
target in RA.  
 
Amelioration of disease following TNF blockade in animal models coincides with 
rapid analgesia (Inglis, Notley et al. 2007; Boettger, Hensellek et al. 2008). In this 
study, mice with CIA had reduced pain thresholds to thermal and mechanical 
hyperalgesia. With anti-IL-17 treatment, thermal and mechanical withdrawal 
latency significantly increased by day 7 post onset of disease and continued to rise 
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to naive levels by the end of the study period.  Significantly reduced inflammation 
in the joint preceded the elevation in pain thresholds. This suggests that anti-IL-17 
is not instantly analgesic, but acts indirectly by down regulating proinflammatory 
cytokines in the joint and reducing nerve sensitisation, allowing the activation 
threshold of nociceptors to rise. Indeed, in a previous study, anti-TNF significantly 
raised mechanical withdrawal latency by day 7 post onset of CIA (Inglis, Notley et 
al. 2007). However, in the same investigation, thermal withdrawal latency was 
significantly increased after anti-TNF by day 3 post onset of arthritis where paw 
swelling was reduced only by day 4, suggesting a more direct action. In this study, 
there was a small rise in thermal latency by day 3 post onset, but this was not 
significant.  
 
Changes in spontaneous behaviour have been regarded as an alternative non-
invasive measure of chronic pain. Anti-TNF therapy has been shown previously to 
restore spontaneous behaviour in animal models of arthritis (Inglis, Notley et al. 
2007; Boettger, Hensellek et al. 2008). Here, LABORAS was used at day 10 post 
onset of arthritis to address whether changes in behaviour occurred during CIA. By 
day 10, climbing and locomotion were significantly reduced in comparison to the 
naive C57BL/6 group, and immobility increased in mice with CIA, correlating with 
a previous study using DBA/1 mice. Grooming, although decreased in the DBA/1 
model, was not significantly different in C57BL/6 mice with CIA. This could be 
due to the C57BL/6 disease being less severe than the DBA/1 (Inglis, Criado et al. 
2007), resulting in less pronounced systemic effects. Anti-IL-17 therapy elicited a 
partial restoration of climbing function, as although significantly increased from 
untreated mice with CIA, it was still decreased when compared to naive controls. 
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As locomotion and immobility were both restored to comparable naive levels, it was 
concluded that minor front paw swelling could hamper climbing but not effect 
general movement.   
 
The results of the previous chapter indicated that the expression of proinflammatory 
cytokines and some cytokine receptors increased in joints of DBA/1 mice with CIA. 
In this study, arthritic paws were again removed at day 10 post onset of arthritis for 
assessment of these cytokines and receptors by qPCR. Consistent with previous 
results, IL-17, TNF, IL-6 and IL-1 were all increased in joints of C57BL/6 mice 
with CIA. When treated with anti-IL-17, all elevated cytokines were decreased to 
naive levels, demonstrating that anti-IL-17 is potently anti-inflammatory in this 
model.  
 
IL-17RA was again found to be upregulated as in Chapter 5, and was down 
regulated with anti-IL-17 treatment. IL-17RC expression was assessed due to its 
importance in IL-17 signalling, but contrastingly was reduced during CIA, and did 
not recover with anti-IL-17 therapy. IL-17 signals through IL-17RA and IL-17RC 
in a heterodimeric complex, but the differing expressions suggest that IL-17RA and 
RC also form complexes with other IL-17R homologs in the IL-17R family. Indeed, 
IL-17RA has recently been considered to also bind with IL-17RB (Gaffen 2009). 
IL-17E is thought to signal through the IL-17RA/RB (Gaffen 2009). IL-17E is 
associated with Th2 responses (Pan, French et al. 2001), and induces expression of 
IL-4 (Fort, Cheung et al. 2001). Furthermore, IL-17E has been implicated in 
regulation of Th17 function during autoimmunity (Kleinschek, Owyang et al. 2007). 
It is therefore speculative, but there is a potential paradoxical role for IL-17RA. In 
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short, by forming a complex with IL-17RC, IL-17 can enhance the inflammatory 
response through induction of other proinflammatory cytokines (Ho and Gaffen 
2010; Ho, Shen et al. 2010; Hu, Ota et al. 2010), but by IL-17RA forming a 
complex with IL-17RB, IL-17E can generate an anti-inflammatory response, to 
regulate inflammation. With IL-17 and its homologs signalling so poorly 
understood, it is impossible to know whether the upregulation of IL-17RA enhances 
IL-17E signalling or whether reduced IL-17RC denotes regulation of inflammation. 
Further work is required to comprehend the role of these receptors in CIA. 
 
TNFR1 message, like IL-17RC was significantly reduced during CIA and was 
similarly reduced compared to naive mice and arthritic mice with anti-IL-17 
therapy, possibly to limit tissue damage as discussed in Chapter 5. TNFR2 
expression significantly increased during CIA, again this was consistent with the 
DBA/1 profile. TNFR2 expression was down regulated with anti-IL-17 therapy, 
probably due to reduced cellular infiltration. 
 
The production of proinflammatory cytokines in the DRG during arthritis has 
received limited attention. In this study, TNF and IL-1 message were upregulated 
during CIA, and then reduced after anti-IL-17 therapy. IL-6 message was present 
but unchanged in either the CIA or anti-IL-17 groups. IL-17 expression was 
undetermined in any group in the DRG. The DRG can produce proinflammatory 
cytokines from satellite cells and Schwann cells (Armati 2007; Takeda, Takahashi 
et al. 2009), but any infiltration of immune cells into the DRG during CIA is 
unknown. Macrophages express TNF and IL-1 , and infiltrate the DRG during CFA 
induced arthritis (Inglis, Nissim et al. 2005). IL-17RA and IL-17RC were both 
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upregulated during CIA. TNFR1 and TNFR2 also increased during CIA, and 
expression was reduced with anti-IL-17 therapy. As discussed in chapter 5, elevated 
message could be due to cell infiltration or point to a more direct action for these 
cytokines during CIA. To address any potential role for proinflammatory cytokines 
and their receptors in the PNS during arthritis, the cells expressing these cytokines 
must first be identified (e.g. by IHC).  
 
Like the DBA/1 model, TNF and IL-1 were again upregulated in the lumbar spinal 
cord in C57BL/6 mice with CIA and IL-6 was unchanged, and IL-17 only expressed 
in arthritic mice. GFAP message was also elevated; indicating astrogliosis occurs in 
C57BL/6 CIA as well as DBA/1. IL-17RA and IL-17RC message were unchanged 
in all groups, but TNFR1 and TNFR2 were significantly increased, correlating with 
the DBA/1 model. Anti-IL-17 therapy reduced expression of all genes to naive 
levels (with the exception of IL-6, IL-17RA and IL-17RC which remained at naive 
levels throughout). This suggests that anti-IL-17 treatment can mediate central 
changes although whether this is a direct effect or indirect effect via reduction in 
peripheral inflammation needs to be investigated.  
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7.1 Summary of thesis 
 
This project has investigated the role of IL-17 in inflammation and hyperalgesia. 
Firstly, IL-17 induced hyperalgesia was examined by injection of the cytokine into 
the footpads of naive mice. Enhanced pain was measured by the Hargreaves thermal 
hyperalgesia test and Linton weight distribution change test. Neutrophil infiltration 
was assessed using histology with H+E staining and the MPO assay. The influence 
of anti-TNF treatment and TNF receptors on IL-17 induced hyperalgesia were 
explored in this model, along with the importance of neutrophil migration. Chronic 
hyperalgesia was investigated using the CIA model of arthritis. Firstly, the kinetics 
of key cytokines and their receptors were examined in the joints, DRG, and spinal 
cords of mice with CIA. This was repeated in the C57BL/6 model and compared 
with anti-IL-17 treated mice to understand the effects of IL-17 blockade during 
CIA. Hyperalgesia was monitored throughout the disease course using Hargreaves 
for thermal hyperalgesia and Von Frey filaments for mechanical allodynia. 
Spontaneous behaviour was measured using LABORAS. This study has shown that 
IL-17 induces acute hyperalgesia, but this is dependent on TNFR1 and neutrophil 
infiltration. Furthermore, blockade of IL-17 is anti-arthritic and analgesic in CIA. 
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7.2 General Discussion and Future Perspectives 
 
IL-17 is a proinflammatory cytokine that has been implicated in a variety of 
autoimmune diseases, including RA. This thesis has focussed on the role of IL-17 in 
inflammation and hyperalgesia.  
 
Hyperalgesia induced by proinflammatory cytokines is thought to be primarily 
governed by TNF. TNF induces a cascade of cytokines including IL-1, IL-8, IL-6 
and KC, resulting in neutrophil migration and release of mediators (NGF, 
prostaglandins) which act on the peripheral neurons. Blockade of IL-1 and NGF 
prevents TNF induced hyperalgesia (Woolf, Allchorne et al. 1997; Cunha, Verri et 
al. 2005) , but IL-1 induced hyperalgesia is not attenuated in TNFR1
-/-
 mice (Cunha, 
Verri et al. 2005). In addition, administration of soluble IL-1Ra does not 
significantly reduce NGF induced hyperalgesia (Woolf, Allchorne et al. 1997), 
leading to the hypothesis that nerve sensitisation is preceded by this sequence; TNF-
IL-1-NGF (Cunha, Verri et al. 2005). Indeed, with carrageenan induced 
hyperalgesia, TNF is upregulated before IL-1 (Cunha, Verri et al. 2005).  
 
As IL-17 induced hyperalgesia has been shown in this thesis to be dependent on 
TNF and TNFR1 (Chapter 3), it must be considered whether IL-17 has a place in 
the cascade hypothesis. Chapter 4 hypothesised IL-17 induce TNF from resident 
cells to initiate hyperalgesia as it is known that IL-17 induces TNF by 3h post 
stimulation in macrophages. Therefore it is possible that IL-17 triggers the cascade 
through induction of TNF. To investigate this, CFA or carrageenan would be 
injected into the hind paw as described previously (Woolf, Allchorne et al. 1997; 
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Cunha, Verri et al. 2005) and levels of cytokines measured over a 24h period. If 
significant IL-17 levels precede TNF upregulation, then IL-17 could be the 
instigator of the inflammatory cascade.  
 
 
Further study would investigate whether IL-17 blockade in TNF or IL-1 injected 
mice attenuated hyperalgesia. If anti-IL-17 does not prevent hyperalgesia by these 
cytokines, it would suggest that IL-17’s role in inflammatory hyperalgesia is to 
induce TNF. However, IL-17 would have to induce TNF rapidly as TNF is present 
in a significant amount by 1h post carrageenan administration and 3h post CFA 
injection (Woolf, Allchorne et al. 1997; Cunha, Verri et al. 2005).  Consequently, 
IL-17 could potentially have a purely additive role in maintaining inflammation 
rather than instigating it.  
 
A previous study showed that IL-17 acts in synergy with TNF to enhance 
chemokine expression through mRNA stabilisation. In the investigation, IL-17 
treatment was shown to elicit a post-transcription effect on TNF released KC to 
extend the half-life of the KC message (Hartupee, Liu et al. 2007). Thus, to further 
understand the role of IL-17 in inflammation and acute pain, additional experiments 
with a combination injection of TNF and IL-17 would ascertain if neutrophil 
migration was increased due to higher KC mRNA stability, potentially extending 
hyperalgesia in this model. 
 
As acute inflammation does not represent the complexity of the arthritic joint the 
role of IL-17 was investigated in CIA. Results discussed in Chapter 5 indicated 
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that proinflammatory cytokines including IL-17 are upregulated during CIA and 
their receptors are elevated in the DRG. Enhanced expression of TNF and IL-17 
receptors could mean that the DRG is more sensitive to TNF and IL-17 during CIA. 
However, whether IL-17 could act more directly on neurones during CIA is 
unknown. TNF added to C fibres results in nerve discharge after 2 mins (Sorkin, 
Xiao et al. 1997), but the distribution of TNF receptors is not fully understood, thus 
the exact action of TNF here is unknown. To investigate the potential direct actions 
of IL-17 on C fibres, IL-17 could be added directly to C fibres and the action 
measured using whole cell voltage-clamp recordings. It would also be informative 
to determine the location of TNF and IL-17 receptors using IHC on sections from 
the DRG. The use of IHC would also determine whether peripheral immune cells 
infiltrate the DRG during CIA, and therefore increasing receptor levels by 
infiltration of cells, rather that increased expression on resident cells. An analysis of 
infiltrating cells would answer how TNF and IL-1 message levels increase during 
CIA and are reduced with anti-IL-17 therapy (Chapter 6). Although TNF and IL-1 
are known to be produced in the DRG (Armati 2007; Takeda, Takahashi et al. 
2009), if the increase was due to cell infiltration, it would point to an indirect 
mechanism for anti-IL-17 therapy, reducing inflammation in the periphery and 
thereby lowering the amount of immune cells migrating to the DRG. Both Chapter 
5 and 6 indicated a role for astrocytes in CIA with an increase in GFAP. To confirm 
this, further work would assess GFAP protein using immunohistochemistry as 
previously described (Inglis, Notley et al. 2007). As with the DRG, 
immunohistochemistry could establish if elevated cytokine production is de novo, or 
due to infiltration of immune cells. 
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How astrocytes are activated during chronic pain is still an unanswered question, 
but it appears that astrogliosis occurs mainly in the superficial laminae of the dorsal 
horn (Hald 2009). These outer layers is where peripheral sensory neurons, largely 
responsible for nociception project to, releasing neurotransmitters such as glutamate 
at their central terminal. Elevated release of glutamate leads to phosphorylation of 
NMDA receptor, allowing calcium influx into the neuron, enhancing their activity 
(Woolf and Costigan 1999; Jones 2003). An increase in phosphorylated NMDAR 
therefore indicates central sensitisation and can be investigated using Western blot 
techniques using spinal cord protein. Although CIA is now additionally described as 
a model of chronic pain, NMDAR expression has never been investigated in this 
model. 
 
 As the BBB only allows very small molecules to pass through the barrier, anti-IL-
17 antibodies are unlikely to pass directly into the central nervous system. As GFAP 
and pro-inflammatory cytokines are reduced by anti-IL-17 therapy, it is therefore 
assumed that the lowering of inflammation in the periphery diminishes the 
sensitisation of the sensory neurons. This restores the nerve threshold, reducing the 
frequency of nerve firing, and therefore lowers glutamate release. 
 
This hypothesis is supported by data presented in Chapter 6 which shows that 
analgesia occurs after inflammation is attenuated with anti-IL-17 therapy. Indeed, 
the upregulation of pro-inflammatory cytokines was significantly reduced in mice 
treated with anti-IL-17 therapy, indicating a reduction in paw inflammation. To 
ensure that any therapeutic effects are due to IL-17 blockade, further investigations 
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must compare this treatment alongside the IgG isotope control for this drug and the 
vehicle in which it is administered. 
 
Finally, as this thesis has demonstrated that IL-17 induced acute hyperalgesia is 
dependent on TNFR1, it must be considered whether this is true during chronic 
hyperalgesia. Previous studies has indicated that IL-17 acts independently of TNF 
during arthritic conditions (Koenders, Lubberts et al. 2006), but has not been 
investigated in CIA. To answer this, anti-IL-17 would be administered to TNFR1
-/-
 
mice with CIA. Reduction in clinical score, paw swelling and hyperalgesia in the 
TNFR1
-/-
 mice with CIA would therefore mean IL-17 is driving inflammation 
independently of TNF in arthritic conditions.  
 
In conclusion, this thesis has shown that IL-17 does have a role in inflammatory 
hyperalgesia but further work is required to dissect the mechanisms. During acute 
inflammation, IL-17 induced hyperalgesia is dependent on TNF mediated neutrophil 
migration, and IL-17 blockade is analgesic and anti-arthritic during chronic 
hyperalgesia. 
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